睿知中国医院研究地图
候选清单

郑州郑州大学

河南省肿瘤医院

Henan Cancer Hospital

在本站收录的 53 种疾病中,这家医院列在其中 14 种下,依据是它牵头的研究论文,以及它作为牵头方或研究中心登记的试验。

这里展示的是公开记录中的研究活动,不是医疗水平评级。能否为某位患者提供帮助,应由医院和主治医生判断。

这家医院的官网还没有核对。

联系这家医院

河南省肿瘤医院的研究

选择一种疾病,查看背后的论文和试验。 每个方块显示 2021–2025 年牵头的论文数和每年的数量。

只包括本站收录的 53 种疾病。未列出某种疾病,表示在这些记录中这家医院没有达到该病的列出标准,不代表它不诊治该病。 哪些医院会被列出

  1. 鼻咽癌Nasopharyngeal carcinoma1 篇牵头论文
  2. 食管鳞状细胞癌Oesophageal squamous cell carcinoma41 篇牵头论文牵头 4 项开放试验
  3. 肝细胞癌Hepatocellular carcinoma34 篇牵头论文牵头 1 项开放试验
  4. 胃癌Stomach cancer76 篇牵头论文牵头 4 项开放试验
  5. 视网膜母细胞瘤Retinoblastoma0 篇牵头论文
  6. 骨肉瘤Osteosarcoma19 篇牵头论文
  7. 胃肠道间质瘤Gastrointestinal stromal tumour1 篇牵头论文
  8. 神经母细胞瘤Neuroblastoma1 篇牵头论文
  9. 尤文肉瘤Ewing sarcoma0 篇牵头论文
  10. 多发性骨髓瘤Multiple myeloma18 篇牵头论文
  11. B 细胞急性淋巴细胞白血病B-cell acute lymphoblastic leukaemia0 篇牵头论文
  12. 再生障碍性贫血Aplastic anaemia4 篇牵头论文
  13. 血友病 AHaemophilia A1 篇牵头论文
  14. 家族性腺瘤性息肉病Familial adenomatous polyposis1 篇牵头论文

未列出的收录疾病:肝母细胞瘤、脊索瘤、噬血细胞性淋巴组织细胞增生症、β 地中海贫血、非典型溶血性尿毒症综合征、血栓性血小板减少性紫癜、范可尼贫血、视神经脊髓炎谱系疾病、IgG4相关性疾病、重症肌无力、烟雾病、肝豆状核变性、胆道闭锁、抗 NMDA 受体脑炎、大动脉炎、肝包虫病、特发性肺纤维化、肺淋巴管平滑肌瘤病、肌萎缩侧索硬化症、脊髓性肌萎缩症、法布雷病、庞贝病、杜氏肌营养不良、白塞病、Alport 综合征、IgA 肾病、戈谢病、尼曼-匹克病 C 型、成骨不全症、原发性胆汁性胆管炎、原发性硬化性胆管炎、先天性膈疝、先天性巨结肠、遗传性大疱性表皮松解症、遗传性血管性水肿、Leber 遗传性视神经病变、Majeed 综合征、NGLY1 缺乏症、ISG15 缺乏症。

癌症

鼻咽癌

Nasopharyngeal carcinoma

2021–2025 年中国大陆作者发表的 2,375 篇鼻咽癌 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.04%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
1
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 1120232024: 0020242025: 002025

郑州有 4 家医院列在鼻咽癌下全国有 183 家医院列在鼻咽癌下

这家医院参与的开放试验 1

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    A Study of SI-B003 and BL-B01D1+SI-B003 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid Tumors
    分期
    II期
    开始
    2024-01
    登记号
    NCT05956587

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 14 家列出的医院为研究中心临沂、南昌、天津、广州、杭州、柳州、武汉、福州、西安、郑州、重庆

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题放疗技术
论文中的科室放疗科
牵头的论文1
  1. A novel automated planning approach for multi-anatomical sites cancer in Raystation treatment planning system.2023Physica medica : PM : an international journal devoted to the applications of physics to medicine and biology : official journal of the Italian Association of Biomedical Physics (AIFB)
它在 ClinicalTrials.gov 上的全部试验(任何状态)4
  1. A Study of SI-B003 and BL-B01D1+SI-B003 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid Tumors正在招募NCT05956587研究中心II期2024-01 启动
  2. A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Recurrent Metastatic Nasopharyngeal Carcinoma进行中,不再招募NCT05126719研究中心II期2023-04 启动
  3. The Study to Evaluate Toripalimab (JS001) in Patients With Advanced GC, ESCC, NPC, HNSCC状态不明NCT02915432研究中心I/II期2016-12 启动
  4. Nimotuzumab in Combination With Chemoradiation for Nasopharyngeal Cancer状态不明NCT01074021研究中心III期2009-10 启动
PubMed 以外找到的论文(未计入)6
  1. Abstract CT227: Anti-LAG-3 antibody LBL-007 in combination with anti-PD-1 antibody toripalimab, in patients with advanced malignant tumors: A phase Ib/II, open-label, multicenter, dose escalation/expansion study2024Cancer Research会议摘要
  2. Anti-PD-1/TGF-βRII bispecific antibody fusion protein LBL-015 in patients with advanced malignant tumors: A phase I, first-in-human, open-label, multicenter, dose-escalation study.2024Journal of Clinical Oncology会议摘要
  3. Data from Epstein-Barr Virus Induces Lymphangiogenesis and Lympth Node Metastasis via Upregulation of VEGF-C in Nasopharyngeal Carcinoma2023未列出期刊其他
  4. Mitoxantrone hydrochloride liposome injection in the treatment of recurrent/metastatic head and neck cancers: A multicenter, open-label, single-arm, phase Ⅰb study.2022Journal of Clinical Oncology会议摘要
  5. The global, regional, and national burden of nasopharyngeal carcinoma and its attributable risk factors in 204 countries and territories, 1990–20192022Figshare数据集
  6. MA13.08 CHOICE-01: A Phase 3 Study of Toripalimab Versus Placebo in Combination With First-Line Chemotherapy for Advanced NSCLC2021Journal of Thoracic Oncology会议摘要

打开 PubMed 检索ClinicalTrials.gov

癌症

食管鳞状细胞癌

Oesophageal squamous cell carcinoma

2021–2025 年中国大陆作者发表的 2,923 篇食管鳞状细胞癌 PubMed 英文论文中,这家医院牵头了 41 篇,占 1.4%。

牵头论文
41
2021–2025 年
牵头试验
9
任何状态,ClinicalTrials.gov
牵头的开放试验
4
正在或即将招募
作为研究中心的开放试验
6
由其他机构牵头
每年牵头的论文数
2021: 6620212022: 101020222023: 7720232024: 8820242025: 882025

郑州有 6 家医院列在食管鳞状细胞癌下全国有 192 家医院列在食管鳞状细胞癌下

这家医院参与的开放试验 10

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Surgery vs. Radical Chemoradiotherapy for Esophageal SCC After Neoadjuvant Immunochemotherapy
    分期
    III期
    开始
    2026-06
    登记号
    NCT07629817

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:河南省肿瘤医院郑州

  2. 正在招募
    Adjuvant Sintilimab for Locally Advanced Esophageal Squamous Cell Carcinoma
    分期
    III期
    开始
    2022-08
    登记号
    NCT05495152

    年龄 18 岁 至 70 岁(登记的条件)

    牵头:河南省肿瘤医院郑州

  3. 正在招募
    Neo-adjuvant Immunochemotheray Versus Neo-adjuvant Chemotherapy for Resectable Esophageal Carcinoma
    分期
    III期
    开始
    2020-04
    登记号
    NCT04280822

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:河南省肿瘤医院郑州

  4. 正在招募
    Neoadjuvant Chemotherapy Versus Neoadjuvant Chemoradiotherapy for Resectable Locally Advanced Esophageal Cancer (HCHTOG1903)
    分期
    III期
    开始
    2019-10
    登记号
    NCT04138212

    年龄 18 岁 至 70 岁(登记的条件)

    牵头:河南省肿瘤医院郑州

  5. 正在招募
    A Clinical Trial of Ifinatamab Deruxtecan in People With Advanced Esophageal Cancer (MK-3475-06F)
    分期
    I/II期
    开始
    2026-03
    登记号
    NCT07405151

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 7 家列出的医院为研究中心北京、厦门、合肥、徐州、杭州、济南、郑州

  6. 正在招募
    SKB500 Combinations in Patients With Esophageal Squamous Cell Carcinoma
    分期
    II期
    开始
    2026-08
    登记号
    NCT07700667

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 21 家列出的医院为研究中心十堰、南京、南宁、南昌、哈尔滨、天津、太原、成都、昆明、汕头、沈阳、洛阳、石家庄、福州、西安、郑州、重庆、长春

  7. 正在招募
    Comparing ICI Followed By CCRT And CCRT Followed By Immunotherapy In Unresectable LA-ESCC
    分期
    II期
    开始
    2026-07
    登记号
    NCT07733830

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:天津医科大学肿瘤医院;另有 6 家列出的医院为研究中心北京、天津、太原、成都、沈阳、郑州

  8. 正在招募
    A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)
    分期
    III期
    开始
    2025-03
    登记号
    NCT06644781

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 28 家列出的医院为研究中心临沂、北京、南宁、厦门、合肥、哈尔滨、天津、安阳、成都、扬州、新乡、杭州、武汉、汕头、沈阳、洛阳、济南、济宁、福州、郑州、长春

  9. 正在招募
    Substudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06)
    分期
    I/II期
    开始
    2025-07
    登记号
    NCT06780111

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 6 家列出的医院为研究中心北京、南昌、厦门、合肥、徐州、郑州

  10. 正在招募
    A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)
    分期
    I/II期
    开始
    2023-05
    登记号
    NCT05319730

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 7 家列出的医院为研究中心上海、北京、厦门、合肥、新乡、杭州、郑州

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题新辅助与综合治疗手术分子标志物与基因
论文中的科室影像/核医学科放疗科肿瘤内科病理/检验科
牵头的论文41
  1. MR outperformed CT in evaluating RECIST response to neoadjuvant therapy in locally advanced esophageal squamous cell carcinoma.2026European radiology
  2. Prognostic impact of different lymph node staging systems in patients with esophageal squamous cell carcinoma.2026Surgical endoscopy
  3. Recurrence patterns and long-term survival of locally advanced esophageal cancer patients with pathological complete response after different neoadjuvant therapies followed by surgery.2025BMC cancer免费全文
  4. Evaluating the efficacy of adjuvant chemotherapy in cT1b-T2 patients with incidentally discovered positive lymph nodes after esophagectomy for esophageal squamous cell carcinoma: a retrospective cohort study.2025BMC cancer免费全文
  5. Automated segmentation of esophageal squamous cell carcinoma in contrast-enhanced free-breathing 3D-GRE: a comparative study of UNet, nnUNet, and UMamba for tumor delineation.2025BMC medical imaging免费全文
  6. Radiotherapy combined with anlotinib in locoregional recurrent esophageal squamous cell carcinoma after radical surgery: a prospective, Phase II clinical trial.2025British journal of cancer免费全文
  7. Heterogeneity and distribution characteristics of tertiary lymphoid structures predict prognostic outcome in esophageal squamous cell carcinoma.2025Frontiers in immunology免费全文
  8. Single-cell RNA sequencing reveals adrb1 as a sympathetic nerve-regulated immune checkpoint driving T cell exhaustion and impacting immunotherapy in esophageal squamous cell carcinoma.2025Frontiers in immunology免费全文
  9. Optimal lymph node dissection thresholds for early-stage esophageal squamous cell carcinoma: a retrospective multicenter study.2025Surgical endoscopy
  10. Consolidation Chemotherapy Provided Survival Benefit for Esophageal Squamous Cell Carcinoma Patients Who Underwent Concurrent Chemoradiotherapy Lower Than 60 Gy.2025Thoracic cancer免费全文
  11. Multiple diffusion models for predicting pathologic response of esophageal squamous cell carcinoma to neoadjuvant chemotherapy.2024Abdominal radiology (New York)
  12. Neoadjuvant Chemotherapy or Adjuvant Chemotherapy for Esophageal Squamous Cell Carcinoma.2024Annals of surgical oncology
  13. Consolidation chemotherapy after definitive concurrent chemoradiotherapy in patients with inoperable esophageal squamous cell carcinoma: a multicenter non-inferiority phase III randomized clinical trial.2024BMC cancer免费全文
  14. Perioperative toripalimab plus neoadjuvant chemotherapy might improve outcomes in resectable esophageal cancer: an interim analysis of a phase III randomized clinical trial.2024Cancer communications (London, England)RCT免费全文
  15. Intravoxel incoherent motion diffusion-weighted imaging in evaluating preoperative staging of esophageal squamous cell carcinoma : Evaluation of preoperative stage of primary tumour and prediction of lymph node metastases from esophageal ca2024Cancer imaging : the official publication of the International Cancer Imaging Society免费全文
  16. The MRI radiomics signature can predict the pathologic response to neoadjuvant chemotherapy in locally advanced esophageal squamous cell carcinoma.2024European radiology
  17. DDX5 promotes esophageal squamous cell carcinoma growth through sustaining VAV3 mRNA stability.2024Oncogene
  18. First-line benmelstobart plus anlotinib and chemotherapy in advanced or metastatic/recurrent esophageal squamous cell carcinoma: a multi-center phase 2 study.2024Signal transduction and targeted therapy免费全文
  19. Patterns and Influence of Lymph Nodal Metastases After Neoadjuvant Chemotherapy and Surgery for Thoracic Esophageal Squamous Cell Carcinoma.2023Annals of surgical oncology
  20. Prognostic significance of baseline peripheral blood lymphocyte subsets on second-line immunotherapy in advanced esophageal squamous cell carcinoma.2023Asian journal of surgery
  21. HA15 inhibits binding immunoglobulin protein and enhances the efficacy of radiation therapy in esophageal squamous cell carcinoma.2023Cancer science免费全文
  22. Stratification of lymph node metastasis improves diagnostic efficiency in thoracic esophageal squamous cell carcinoma.2023Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus
  23. Survival impact of the number of lymph nodes dissection in patients receiving neoadjuvant chemotherapy for esophageal squamous cell carcinoma.2023Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus
  24. A multicenter randomized, controlled clinical trial of adjuvant sintilimab for esophageal squamous cell carcinoma.2023Future oncology (London, England)RCT
  25. Initial experience with modified en bloc robot-assisted minimally invasive oesophagectomy for thoracic oesophageal squamous cell carcinoma.2023The international journal of medical robotics + computer assisted surgery : MRCAS
  26. Circular RNA hsa_circ_0000277 promotes tumor progression and DDP resistance in esophageal squamous cell carcinoma.2022BMC cancer免费全文
  27. A multi-center, single-arm, phase II study of anlotinib plus paclitaxel and cisplatin as the first-line therapy of recurrent/advanced esophageal squamous cell carcinoma.2022BMC medicine免费全文
  28. Circ_0007624 suppresses the development of esophageal squamous cell carcinoma via targeting miR-224-5p/CPEB3 to inactivate the EGFR/PI3K/AKT signaling.2022Cellular signalling
  29. Quantitative RECIST derived from multiparametric MRI in evaluating response of esophageal squamous cell carcinoma to neoadjuvant therapy.2022European radiology
  30. Development and validation of MRI-based radiomics signatures models for prediction of disease-free survival and overall survival in patients with esophageal squamous cell carcinoma.2022European radiologyRCT
  31. Characterization of the Intra-tumoral B Cell Immunoglobulin Repertoire Is of Prognostic Value for Esophageal Squamous Cell Carcinoma.2022Frontiers in immunology免费全文
  32. Targeting stearoyl-coa desaturase enhances radiation induced ferroptosis and immunogenic cell death in esophageal squamous cell carcinoma.2022Oncoimmunology免费全文
  33. Prognostic Value of Lactate Dehydrogenase in Second-Line Immunotherapy for Advanced Esophageal Squamous Cell Carcinoma.2022Pathology oncology research : POR免费全文
  34. Comparative Clinical Efficacy of 'Concurrent Chemoradiotherapy (CCRT) and Anlotinib' Than CCRT in Patients with Locally Advanced ESCC.2022Technology in cancer research & treatment免费全文
  35. Adjuvant Chemotherapy for Node-positive Esophageal Squamous Cell Carcinoma Improves Survival.2022The Annals of thoracic surgery
  36. Fusobacterium nucleatum predicts a high risk of metastasis for esophageal squamous cell carcinoma.2021BMC microbiology免费全文
  37. Long non-coding RNA XIST promotes the progression of esophageal squamous cell carcinoma through sponging miR-129-5p and upregulating CCND1 expression.2021Cell cycle (Georgetown, Tex.)免费全文
  38. THAP9-AS1/miR-133b/SOX4 positive feedback loop facilitates the progression of esophageal squamous cell carcinoma.2021Cell death & disease免费全文
  39. The value of intravoxel incoherent motion diffusion-weighted imaging in predicting the pathologic response to neoadjuvant chemotherapy in locally advanced esophageal squamous cell carcinoma.2021European radiology
  40. The Sequence of Chemotherapy and Toripalimab Might Influence the Efficacy of Neoadjuvant Chemoimmunotherapy in Locally Advanced Esophageal Squamous Cell Cancer-A Phase II Study.2021Frontiers in immunologyRCT免费全文
  41. lncRNA PART1, manipulated by transcriptional factor FOXP2, suppresses proliferation and invasion in ESCC by regulating the miR‑18a‑5p/SOX6 signaling axis.2021Oncology reports免费全文
中文论文(未计入)1
  1. [Application value of CT examination of lymph node short diameter in evaluating cardia-left gastric lymph node metastasis in thoracic esophageal squamous cell carcinoma].2023Zhonghua zhong liu za zhi [Chinese journal of oncology]
它在 ClinicalTrials.gov 上的全部试验(任何状态)36
  1. Surgery vs. Radical Chemoradiotherapy for Esophageal SCC After Neoadjuvant Immunochemotherapy正在招募NCT07629817牵头方III期2026-06 启动
  2. Adjuvant Sintilimab for Locally Advanced Esophageal Squamous Cell Carcinoma正在招募NCT05495152牵头方III期2022-08 启动
  3. Neo-adjuvant Immunochemotheray Versus Neo-adjuvant Chemotherapy for Resectable Esophageal Carcinoma正在招募NCT04280822牵头方III期2020-04 启动
  4. Neoadjuvant Chemotherapy Versus Neoadjuvant Chemoradiotherapy for Resectable Locally Advanced Esophageal Cancer (HCHTOG1903)正在招募NCT04138212牵头方III期2019-10 启动
  5. Prospective Phase II Clinical Study of Neoadjuvant Chemoradiotherapy Combined With PD-1/PD-L1 Inhibitors in the Treatment of Locally Advanced Resectable Esophageal Squamous Cell Carcinoma进行中,不再招募NCT06888531牵头方II期2025-03 启动
  6. TQB2450 Solution for Injection (TQB2450)+Paclitaxel+Cisplatin ± Anlotinib in the Treatment of Esophageal Cancer.状态不明NCT05013697牵头方II期2021-09 启动
  7. Paclitaxel and DDP Combined With Anlotinib in the First-line Treatment for Patients With Advanced Esophageal Squamous Cell Carcinoma(ESCC).状态不明NCT04063683牵头方II期2019-10 启动
  8. Teripalimab Plus Chemotherapy in Local Advanced Esophageal Cancer状态不明NCT03985670牵头方II期2019-07 启动
  9. Neoadjuvant Chemotherapy Versus Surgery Alone for Esophageal Squamous Cell Carcinoma已完成NCT02395705牵头方III期2015-06 启动
  10. Comparing ICI Followed By CCRT And CCRT Followed By Immunotherapy In Unresectable LA-ESCC正在招募NCT07733830研究中心II期2026-07 启动
  11. SKB500 Combinations in Patients With Esophageal Squamous Cell Carcinoma正在招募NCT07700667研究中心II期2026-08 启动
  12. A Clinical Trial of Ifinatamab Deruxtecan in People With Advanced Esophageal Cancer (MK-3475-06F)正在招募NCT07405151研究中心I/II期2026-03 启动
  13. Substudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06)正在招募NCT06780111研究中心I/II期2025-07 启动
  14. A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)正在招募NCT06644781研究中心III期2025-03 启动
  15. A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)正在招募NCT05319730研究中心I/II期2023-05 启动
  16. A Study to Evaluate LBL-007 in Combination With Tislelizumab Plus Chemotherapy in Participants With Unresectable Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma已完成NCT06010303研究中心II期2023-11 启动
  17. Study To Investigate the Efficacy and Safety of Sitravatinib in Combination With Tislelizumab in Participants With Esophageal Squamous Cell Carcinoma已终止NCT05461794研究中心II期2022-10 启动
  18. A Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX07 Combination Therapy or Monotherapy in Patients With Advanced ESCC状态不明NCT05221658研究中心II期2022-08 启动
  19. Real-world Experience of ICIs Plus Chemotherapy for Advanced ESCC.已完成NCT05142709研究中心2021-10 启动
  20. Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) Combined With or Without Anti-TIGIT Monoclonal Antibody Ociperlimab (BGB-A1217) in Participants With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma已完成NCT04732494研究中心II期2021-03 启动
  21. Perioperative Toripalimab (JS001) Combined With Neoadjuvant Chemotherapy in Patients With Resectable Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma进行中,不再招募NCT04848753研究中心III期2021-05 启动
  22. JMT101 Combined With Afatinib in Patients With Advanced Esophageal Squamous Cell Carcinoma After Standard Therapy状态不明NCT05164848研究中心I期2021-12 启动
  23. JAB-3068 Activity in Adult Patients With Advanced Solid Tumors已完成NCT04721223研究中心I/II期2021-04 启动
  24. A Study of T3011 Administered Via Intratumoral Injection in Patients With Advanced Solid Tumors状态不明NCT05602792研究中心I/II期2020-04 启动
  25. A Study of Atezolizumab Plus Tiragolumab in Combination With Paclitaxel and Cisplatin Compared With Paclitaxel and Cisplatin as First-Line Treatment in Participants With Unresectable Locally Advanced, Unresectable Recurrent, or Metastatic Esophageal Carcinoma已完成NCT04540211研究中心III期2020-10 启动
  26. A Study to Investigate Tislelizumab (BGB-A317) Versus Placebo in Combination With Concurrent Chemoradiotherapy in Participants With Localized Esophageal Squamous Cell Carcinoma已完成NCT03957590研究中心III期2019-06 启动
  27. A Study of CS1001 in Subjects With Esophageal Squamous Cell Carcinoma已完成NCT04187352研究中心III期2019-12 启动
  28. A Study of Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma已完成NCT03430843研究中心III期2018-01 启动
  29. Safety and Efficacy of SCT200 in Patients With Advanced Esophageal Squamous Cell Carcinoma状态不明NCT03817567研究中心I/II期2018-07 启动
  30. A Study of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma已完成NCT03783442研究中心III期2018-12 启动
  31. Real-world Experience of ICIs Plus Chemotherapy With or Without Radiotherapy for Advanced ESCC.已完成NCT06190652研究中心2018-10 启动
  32. Study of Pembrolizumab (MK-3475) Versus Investigator's Choice of Chemotherapy for Participants With Advanced Esophageal/Esophagogastric Junction Carcinoma That Progressed After First-Line Therapy (MK-3475-181/KEYNOTE-181)-China Extension Study已完成NCT03933449研究中心III期2016-12 启动
  33. The Study to Evaluate Toripalimab (JS001) in Patients With Advanced GC, ESCC, NPC, HNSCC状态不明NCT02915432研究中心I/II期2016-12 启动
  34. Study of Anlotinib in Patients With Esophageal Squamous Cell Carcinoma (ALTER1102)已完成NCT02649361研究中心II期2016-01 启动
  35. A Phase III Study of Nimotuzumab Plus Concurrent Chemoradiotherapy in Loco-regional Esophageal Squamous Cell Carcinoma状态不明NCT02409186研究中心III期2015-03 启动
  36. Irinotecan Plus S1 Versus S1 in Patients With Previously Treated Advanced Esophageal Cancer: ESWN 01 Trial状态不明NCT02319187研究中心III期2014-12 启动
PubMed 以外找到的论文(未计入)42
  1. 271O Final analysis and biomarker evaluation of JUPITER-06: A phase III trial of toripalimab plus chemotherapy in advanced or metastatic esophageal squamous cell carcinoma2025Annals of Oncology论文
  2. 349. PATHOLOGIC COMPLETE RESPONSE IN ESOPHAGEAL SQUAMOUS CELL CANCER: DO DIVERSE NEOADJUVANT MODALITIES PREDICT PROGNOSTIC DIFFERENCES?2025Diseases of the Esophagus论文
  3. 396. IRAE IN PHASE III STUDY ON NEOADJUVANT CHEMOTHERAPY VERSUS PERIOPERATIVE TORIPALIMAB PLUS NEOADJUVANT CHEMOTHERAPY FOR ESOPHAGEAL SQUAMOUS CELL CARCINOMA: HCHTOG19092025Diseases of the Esophagus论文
  4. An interim analysis of phase III study on neoadjuvant chemotherapy versus perioperative toripalimab plus neoadjuvant chemotherapy for locally advanced esophageal squamous cell carcinoma: Henan Cancer Hospital Thoracic Oncology Group 1909 (H2025Journal of Clinical Oncology会议摘要
  5. CDK15 Promotes Esophageal Squamous Cell Carcinoma Progression by Phosphorylating HK2 and Regulating Glycolysis2025International Journal of Radiation Oncology*Biology*Physics会议摘要
  6. Efficacy and safety results of a multi-center phase II study of utidelone injection in combination with PD-1 inhibitor and chemotherapy for the first-line treatment of advanced gastric and esophagus cancers.2025Journal of Clinical Oncology会议摘要
  7. Preliminary results of the ALTER-E009 study: Efficacy and safety of anlotinib combined with radiotherapy in patients with locally advanced or metastatic esophageal squamous cell carcinoma (ESCC)—A multicenter, multi-cohort retrospective exp2025Journal of Clinical Oncology会议摘要
  8. The lost evidence: A phase III, multicenter randomized controlled trial of neoadjuvant chemotherapy paclitaxel plus cisplatin versus surgery alone for stage IIA–IIIB esophageal squamous cell carcinoma.2025Journal of Clinical Oncology会议摘要
  9. Updated results of the ALTER-E00 study: Efficacy and safety of anlotinib combined with radiotherapy in patients with locally advanced or metastatic esophageal squamous cell carcinoma (ESCC): A multi-center, multi-cohort retrospective explor2025Journal of Clinical Oncology论文
  10. A Phase II Clinical Trial of Radiotherapy Combined with Anlotinib in Locoregional Recurrent Esophageal Squamous Cell Carcinoma after Radical Surgery2024International Journal of Radiation Oncology*Biology*Physics论文
  11. A single-arm, open-label phase II clinical trial of SHR-1210 (camrelizumab) in combination with nimotuzumab in the second-line treatment of advanced esophageal squamous cell carcinoma.2024Journal of Clinical Oncology会议摘要
  12. Abstract CT227: Anti-LAG-3 antibody LBL-007 in combination with anti-PD-1 antibody toripalimab, in patients with advanced malignant tumors: A phase Ib/II, open-label, multicenter, dose escalation/expansion study2024Cancer Research会议摘要
  13. Concordance among three programmed death-ligand 1 (PD-L1) scoring methods and their association with clinical outcomes of tislelizumab (TIS) monotherapy in esophageal squamous cell carcinoma (ESCC).2024Journal of Clinical Oncology会议摘要
  14. Development of a new EGFR-VHH-CAR T-cell therapy for treatment of esophageal squamous cell carcinoma2024Research Square预印本
  15. First-line TQB2450 plus anlotinib combined with paclitaxel and cisplatin for advanced esophageal squamous cell carcinoma (ESCC): Update results of a multicenter phase II trial.2024Journal of Clinical Oncology会议摘要
  16. PDIA6 promotes the progression of ESCC via AKT1/mTOR signal pathway by forming disulfide-dependent TRAF42024Research Square预印本
  17. The Prognostic Significance of Tertiary Lymphoid Structure Assessment with Hematoxylin and Eosin Sections in Esophageal Squamous Cell Carcinoma2024Research Square预印本
  18. Tislelizumab plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy for elderly patients with inoperable locally advanced esophageal squamous cell carcinoma: A multicenter, randomized, parallel-controlled, phase II clinical t2024Journal of Clinical Oncology会议摘要
  19. 1573P Involved field and elective nodal irradiation presented similar treatment efficiency in concurrent chemoradiation for locally advanced ESCC2023Annals of Oncology论文
  20. 95P A single-arm, multicenter phase II trial evaluating TQB2450 plus anlotinib combined with paclitaxel and cisplatin in first-line treatment of advanced esophageal squamous cell carcinoma (ESCC)2023Immuno-Oncology Technology论文
  21. KC1036, a novel oral multi-kinase inhibitor, in patients with previously treated advanced esophageal squamous cell carcinoma (ESCC): Results from a multicenter, single-arm phase II trial.2023Journal of Clinical Oncology会议摘要
  22. O-4 GEMSTONE-304: A phase 3 study of sugemalimab plus chemotherapy versus chemotherapy as first-line treatment of patients with unresectable locally advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC)2023Annals of Oncology论文
  23. TQB2450 plus anlotinib combined with paclitaxel and cisplatin as first-line treatment of advanced esophageal squamous cell carcinoma (ESCC): Update results of a single-arm, multicenter phase Ⅱ trial.2023Journal of Clinical Oncology会议摘要
  24. 164P TQB2450 plus anlotinib combined with paclitaxel and cisplatin as first-line treatment of advanced esophageal squamous cell carcinoma (ESCC): A single-arm, multicenter phase Ⅱ trial2022Immuno-Oncology Technology论文
  25. 476. SONIC HEDGEHOG POSITIVE EXPRESSION IS ASSOCIATED WITH PROGNOSIS AND THE RESPONSE OF ESOPHAGEAL SQUAMOUS CELL CARCINOMA TO NEOADJUVANT CHEMOTHERAPY2022Diseases of the Esophagus论文
  26. Effect of postoperative adjuvant chemotherapy on esophageal squamous cell carcinoma patients with lymphovascular invasion and without lymph node metastasis2022Research Square预印本
  27. Nimotuzumab plus concurrent chemo-radiotherapy versus chemo-radiotherapy in unresectable locally advanced esophageal squamous cell carcinoma (ESCC): Interim analysis from a prospective, randomized-controlled, double-blinded, multicenter, an2022Journal of Clinical Oncology会议摘要
  28. Randomized, phase 3 study of second-line tislelizumab versus chemotherapy in advanced or metastatic esophageal squamous cell carcinoma, RATIONALE 302: Asia subgroup.2022Journal of Clinical Oncology会议摘要
  29. Randomized, phase 3 study of second-line tislelizumab vs chemotherapy in advanced or metastatic esophageal squamous cell carcinoma, RATIONALE 302: Asia subgroup.2022Journal of Clinical Oncology会议摘要
  30. Update results of paclitaxel and cisplatin in combination with anlotinib as first-line regimen for patients with advanced ESCC: A multicenter, single-arm, open-label phase Ⅱ clinical trial.2022Journal of Clinical Oncology会议摘要
  31. 1373MO JUPITER-06: A randomized, double-blind, phase III study of toripalimab versus placebo in combination with first-line chemotherapy for treatment naive advanced or metastatic esophageal squamous cell carcinoma (ESCC)2021Annals of Oncology论文
  32. 285 RIGHT COMPARED WITH LEFT THORACIC APPROACH ESOPHAGECTOMY FOR PATIENTS WITH MIDDLE ESOPHAGEAL SQUAMOUS CELL CARCINOMA2021Diseases of the Esophagus论文
  33. 624 A PHASE III STUDY ON NEOADJUVANT TORIPALIMAB PLUS CHEMOTHERAPY VERSUS NEOADJUVANT CHEMOTHERAPY FOR LOCALLY RESECTABLE ESOPHAGEAL SQUAMOUS CELL CARCINOMA2021Diseases of the Esophagus论文
  34. Analysis of Key Pathways, Genes and Immune Cell Infiltration in Metastatic Esophageal Squamous Cell Carcinoma Based on Bioinformatics2021Research Square预印本
  35. CS1001-304: A phase III study of fluorouracil and cisplatin (FP) with CS1001, an anti-PD-L1 antibody, or placebo in unresectable locally advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC).2021Journal of Clinical Oncology会议摘要
  36. First-line pembrolizumab plus chemotherapy versus chemotherapy in patients with advanced esophageal cancer: Chinese subgroup analysis of KEYNOTE-590.2021Journal of Clinical Oncology会议摘要
  37. Larotinib in Patients with Advanced and Previously Treated Esophageal Squamous Cell Carcinoma with Epidermal Growth Factor Receptor Overexpression or Amplification: An Open-Label, Multicenter Phase 1b Study2021Research Square预印本
  38. Larotinib in Patients with Advanced and Previously Treated Esophageal Squamous Cell Carcinoma with Epidermal Growth Factor Receptor Overexpression or Amplification: An Open-Label, Multicenter Phase 1b Study2021Research Square预印本
  39. RATIONALE 302: Randomized, phase 3 study of tislelizumab versus chemotherapy as second-line treatment for advanced unresectable/metastatic esophageal squamous cell carcinoma.2021Journal of Clinical Oncology会议摘要
  40. The sequence of chemotherapy and anti-PD-1 antibody influence the efficacy of neoadjuvant immunochemotherapy in locally advanced esophageal squamous cell cancer: A phase II study.2021Journal of Clinical Oncology会议摘要
  41. Update results of paclitaxel and cisplatin in combination with anlotinib as first-line regimen for advanced esophageal squamous cell carcinoma (ESCC): A multicenter, single-arm, open-label phase Ⅱ clinical trial.2021Journal of Clinical Oncology会议摘要
  42. Update results of paclitaxel and cisplatin in combination with anlotinib as first-line regimen for patients with advanced ESCC: A multicenter, single-arm, open-label phase Ⅱ clinical trial.2021Journal of Clinical Oncology会议摘要

打开 PubMed 检索ClinicalTrials.gov

癌症

肝细胞癌

Hepatocellular carcinoma

2021–2025 年中国大陆作者发表的 14,765 篇肝细胞癌 PubMed 英文论文中,这家医院牵头了 34 篇,占 0.2%。

牵头论文
34
2021–2025 年
牵头试验
3
任何状态,ClinicalTrials.gov
牵头的开放试验
1
正在或即将招募
作为研究中心的开放试验
11
由其他机构牵头
每年牵头的论文数
2021: 6620212022: 7720222023: 6620232024: 7720242025: 662025

郑州有 3 家医院列在肝细胞癌下全国有 194 家医院列在肝细胞癌下

这家医院参与的开放试验 12

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Backline Treatment of Advanced Hepatocellular Carcinoma With Palbociclib
    分期
    不分期
    开始
    2024-01
    登记号
    NCT06478927

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:河南省肿瘤医院郑州

  2. 正在招募
    MRG006A Combination Therapy for Advanced Hepatocellular Carcinoma (Phase I/II)
    分期
    I/II期
    开始
    2026-04
    登记号
    NCT07479485

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 7 家列出的医院为研究中心北京、南京、天津、福州、郑州

  3. 正在招募
    A Phase Ib/II Trial to Evaluate the Efficacy and Safety of HH-009 for the Treatment of FGF19-positive Advanced or Unresectable HCC
    分期
    I/II期
    开始
    2026-05
    登记号
    NCT07547553

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 17 家列出的医院为研究中心上海、北京、南京、南宁、南昌、合肥、哈尔滨、天津、广州、沈阳、福州、蚌埠、郑州、长春

  4. 正在招募
    HAI or IV of Adebrelimab, Combined With Bevacizumab and HAI of FOLFOX for Advanced Unresectable Hepatocellular Carcinoma
    分期
    II期
    开始
    2025-01
    登记号
    NCT06737913

    年龄 18 岁 至 未注明(登记的条件)

    牵头:中山大学肿瘤防治中心;另有 1 家列出的医院为研究中心广州、郑州

  5. 正在招募
    Phase I Clinical Study To Evaluate Pharmacokinetic Profile, Safety, Efficacy and Immunogenicity Of Ipilimumab Biosimilar HLX13 Vs. YERVOY® (US-Sourced YERVOY®) As A First-Line Treatment For Patients With Unresectable Hepatocellular Carcinoma
    分期
    I期
    开始
    2025-11
    登记号
    NCT07176650

    年龄 18 岁 至 65 岁(登记的条件)

    牵头方不是列出的医院;另有 27 家列出的医院为研究中心上海、北京、南京、南宁、南昌、合肥、哈尔滨、天津、广州、成都、杭州、武汉、沈阳、海口、石家庄、福州、蚌埠、西安、郑州、长春

  6. 正在招募
    Study to Evaluate the Efficacy and Safety of Neo-Adjuvant TACE and Atezolizumab Plus Bevacizumab Therapy for High-Risk Recurrent Hepatocellular Carcinamo
    分期
    II期
    开始
    2025-11
    登记号
    NCT07239245

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:中国医学科学院肿瘤医院;另有 2 家列出的医院为研究中心北京、沈阳、郑州

  7. 正在招募
    ABSK-011+BSC vs. Placebo+BSC in Previously Treated Advanced HCC With FGF19 Overexpression
    分期
    II期
    开始
    2025-06
    登记号
    NCT07327034

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 39 家列出的医院为研究中心上海、北京、南京、南宁、南昌、南通、合肥、天津、广州、徐州、成都、杭州、桂林、武汉、沈阳、济南、福州、西安、赣州、郑州、重庆、银川、长春、长沙

  8. 正在招募
    MDN-001 Injection for the Treatment of Unresectable Primary Hepatocellular Carcinoma.
    分期
    I期
    开始
    2025-08
    登记号
    NCT07391839

    年龄 18 岁 至 80 岁(登记的条件)

    牵头方不是列出的医院;另有 8 家列出的医院为研究中心上海、南京、合肥、广州、杭州、济南、福州、郑州

  9. 正在招募
    A Study of AK104+Lenvatinib in Combination With Transarterial Chemoembolization (TACE) Versus TACE in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma
    分期
    III期
    开始
    2024-08
    登记号
    NCT06371157

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 4 家列出的医院为研究中心南京、杭州、郑州、长沙

  10. 正在招募
    Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.
    分期
    III期
    开始
    2023-05
    登记号
    NCT05862337

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 46 家列出的医院为研究中心上海、乌鲁木齐、兰州、北京、南充、南宁、南昌、南通、台州、合肥、大连、天津、宁波、常州、广州、成都、杭州、沈阳、泸州、济南、海口、温州、福州、蚌埠、西安、郑州、重庆、长春、长沙

  11. 正在招募
    A Phase I Clinical Study of Intratumoral Injection Oncolytic Vaccinia Virus GC001 in Patient With Advanced Solid Tumors
    分期
    I期
    开始
    2023-04
    登记号
    NCT06508307

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 1 家列出的医院为研究中心郑州

  12. 即将招募
    A Clinical Trial Assessing the Safety and Efficacy of Biodegradable Magnesium Embolic Microspheres for Primary Hepatocellular Carcinoma
    分期
    III期
    开始
    2025-01
    登记号
    NCT06779461

    年龄 18 岁 至 80 岁(登记的条件)

    牵头方不是列出的医院;另有 7 家列出的医院为研究中心上海、兰州、南京、天津、广州、蚌埠、郑州

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题复发与预后局部治疗(消融、TACE、HAIC)免疫与靶向药物
论文中的科室普外/肝胆胰外科影像/核医学科放疗科肿瘤内科
牵头的论文34
  1. Development of a circulating tumor DNA methylation biomarker panel for hepatocellular carcinoma detection.2026European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  2. SAE1 emerges as a pan-cancer driver and key regulator of HCC metastasis.2026Journal of advanced research免费全文
  3. Adjuvant Transarterial Chemoembolization in Resected Macrotrabecular-massive Hepatocellular Carcinoma (ATAC-MACRO): A Multicenter Real-world Retrospective Study.2025Academic radiology
  4. CircMFN2/miR-361-3p/ELK1 feedback loop promotes glutaminolysis and the progression of hepatocellular carcinoma.2025Cancer letters
  5. Efficacy and safety of DEB-TACE combined with transarterial TQB2450 infusion and oral Anlotinib as first-line treatment in advanced hepatocellular carcinoma: a single-arm phase II study.2025Frontiers in immunology免费全文
  6. How different body compositions affect the prognosis of HCC undergoing immunotherapy: the paradoxical phenomenon of BMI.2025La Radiologia medica
  7. Glutamate promotes CCL2 expression to recruit tumor-associated macrophages by restraining EZH2-mediated histone methylation in hepatocellular carcinoma.2025Oncoimmunology免费全文
  8. Analysis of the efficacy of splenic artery superselective embolization in cirrhosis with hepatocellular carcinoma.2025PloS one免费全文
  9. Relationship between TIGIT expression on T cells and the prognosis of patients with hepatocellular carcinoma.2024BMC cancer免费全文
  10. UCHL5 promotes hepatocellular carcinoma progression by promoting glycolysis through activating Wnt/β-catenin pathway.2024BMC cancer免费全文
  11. Laparoscopic liver resection versus radiofrequency ablation for caudate lobe solitary hepatocellular carcinoma: A propensity score matching study.2024Cancer medicine
  12. Histamine-related genes participate in the establishment of an immunosuppressive microenvironment and impact the immunotherapy response in hepatocellular carcinoma.2024Clinical and experimental medicine免费全文
  13. Antiviral therapy can effectively suppress irAEs in HBV positive hepatocellular carcinoma treated with ICIs: validation based on multi machine learning.2024Frontiers in immunology免费全文
  14. Pan-cancer analysis of DCTN2 and its tumour-promoting role in HCC by modulating the AKT pathway.2024Journal of cellular and molecular medicine免费全文
  15. CD69+ Vδ1γδ T cells are anti-tumor subpopulations in hepatocellular carcinoma.2024Molecular immunology
  16. Association of hepatitis B virus DNA levels with overall survival for advanced hepatitis B virus-related hepatocellular carcinoma under immune checkpoint inhibitor therapy.2023Cancer immunology, immunotherapy : CII免费全文
  17. Matrix metalloproteinase 1 is a poor prognostic biomarker for patients with hepatocellular carcinoma.2023Clinical and experimental medicine
  18. Transarterial Chemoembolization Combined With Apatinib Plus PD-1 Inhibitors for Hepatocellular Carcinoma With Portal Vein Tumor Thrombus: A Multicenter Retrospective Study.2023Clinical and translational gastroenterology免费全文
  19. The MAPS-CRAFITY score: a novel efficacy predictive tool for unresectable hepatocellular carcinoma treated with targeted therapy plus immunotherapy.2023Hepatology international
  20. Correlation of Serum Chemokine Ligand 14 with Barcelona Clinic Liver Cancer Stage, Lymphocyte Profile, and Response to Transarterial Chemoembolization in Patients with Hepatocellular Carcinoma.2023Journal of vascular and interventional radiology : JVIR
  21. Nuclear translocation of YAP drives BMI-associated hepatocarcinogenesis in hepatitis B virus infection.2023Liver international : official journal of the International Association for the Study of the Liver
  22. Radiofrequency ablation combined with transarterial chemoembolization in treatment of hepatocellular carcinoma adjacent to the second hepatic hilus.2022Abdominal radiology (New York)免费全文
  23. HBX suppresses PTEN to promote the malignant progression of hepatocellular carcinoma through mi-R155 activation.2022Annals of hepatology
  24. Risk of Liver Cirrhosis in HBV/HCV-Infected Individuals with First-Degree Relatives Who Have Liver Cancer: Development and Validation of a Simple Model.2022Cancer prevention research (Philadelphia, Pa.)
  25. Molecular subtypes based on Wnt-signaling gene expression predict prognosis and tumor microenvironment in hepatocellular carcinoma.2022Frontiers in immunology免费全文
  26. Efficacy and safety of atezolizumab plus bevacizumab combined with hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma.2022Frontiers in immunology免费全文
  27. MiR-122 radiosensitize hepatocellular carcinoma cells by suppressing cyclin G1.2022International journal of radiation biology
  28. Useful genes for predicting the efficacy of transarterial chemoembolization in hepatocellular carcinoma.2022Journal of cancer research and therapeutics
  29. Gastroesophageal junction cancer with hepatic metastasis: Effective Treatment using microsphere embolization combined with transarterial infusion chemotherapy.2021Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the LiverRCT
  30. Clinical observation of local intervention combined with camrelizumab and apatinib in the treatment of metastatic soft-tissue sarcoma.2021Journal of cancer research and therapeutics
  31. HBXIP drives metabolic reprogramming in hepatocellular carcinoma cells via METTL3-mediated m6A modification of HIF-1α.2021Journal of cellular physiology
  32. An Integrated Transcriptomics and Proteomics Analysis Implicates lncRNA MALAT1 in the Regulation of Lipid Metabolism.2021Molecular & cellular proteomics : MCP免费全文
  33. Silencing the Expression of Cyclin G1 Enhances the Radiosensitivity of Hepatocellular Carcinoma In Vitro and In Vivo by Inducing Apoptosis.2021Radiation research
  34. DEAD-box Helicase 27 Promotes Hepatocellular Carcinoma Progression Through ERK Signaling.2021Technology in cancer research & treatment免费全文
中文论文(未计入)6
  1. [Advances in the application of selective internal radiation therapy in the treatment of hepatocellular carcinoma].2025Zhonghua nei ke za zhi
  2. [Current status, challenges and strategy of combination treatment of local interventional therapy and immunotherapy for primary hepatocellular carcinoma].2022Zhonghua nei ke za zhi
  3. [Curative effect analysis of ultrasound-guided percutaneous radiofrequency ablation for caudate lobe hepatocellular carcinoma].2021Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology免费全文
  4. [Correlation analysis of Ki67, Ck19 with clinicopathological features and apparent diffusion coefficient value of hepatocellular carcinoma].2021Zhonghua yi xue za zhi
  5. [Effect and mechanism of siRNA targeting α-enolase gene combined with paclitaxel on proliferation, invasion and apoptosis of hepatocellular carcinoma cell].2021Zhonghua zhong liu za zhi [Chinese journal of oncology]
  6. [Effects of LINC00839 targeting miR-3666 on proliferation, migration and invasion of hepatocellular carcinoma cells].2021Zhonghua zhong liu za zhi [Chinese journal of oncology]
它在 ClinicalTrials.gov 上的全部试验(任何状态)35
  1. Backline Treatment of Advanced Hepatocellular Carcinoma With Palbociclib正在招募NCT06478927牵头方不分期2024-01 启动
  2. Sequential T and I With H101 Via HAI for BCLC C Stage HCC: A Prospective Single-Center Single-Arm Pilot Study状态不明NCT06685354牵头方II期2024-11 启动
  3. Real-World Effectiveness of Regorafenib in the Treatment of Patients With Hepatocellular Carcinoma状态不明NCT05024539牵头方(推断)2021-06 启动
  4. A Phase Ib/II Trial to Evaluate the Efficacy and Safety of HH-009 for the Treatment of FGF19-positive Advanced or Unresectable HCC正在招募NCT07547553研究中心I/II期2026-05 启动
  5. MRG006A Combination Therapy for Advanced Hepatocellular Carcinoma (Phase I/II)正在招募NCT07479485研究中心I/II期2026-04 启动
  6. Study to Evaluate the Efficacy and Safety of Neo-Adjuvant TACE and Atezolizumab Plus Bevacizumab Therapy for High-Risk Recurrent Hepatocellular Carcinamo正在招募NCT07239245研究中心II期2025-11 启动
  7. MDN-001 Injection for the Treatment of Unresectable Primary Hepatocellular Carcinoma.正在招募NCT07391839研究中心I期2025-08 启动
  8. HAI or IV of Adebrelimab, Combined With Bevacizumab and HAI of FOLFOX for Advanced Unresectable Hepatocellular Carcinoma正在招募NCT06737913研究中心II期2025-01 启动
  9. ABSK-011+BSC vs. Placebo+BSC in Previously Treated Advanced HCC With FGF19 Overexpression正在招募NCT07327034研究中心II期2025-06 启动
  10. Phase I Clinical Study To Evaluate Pharmacokinetic Profile, Safety, Efficacy and Immunogenicity Of Ipilimumab Biosimilar HLX13 Vs. YERVOY® (US-Sourced YERVOY®) As A First-Line Treatment For Patients With Unresectable Hepatocellular Carcinoma正在招募NCT07176650研究中心I期2025-11 启动
  11. A Clinical Trial Assessing the Safety and Efficacy of Biodegradable Magnesium Embolic Microspheres for Primary Hepatocellular Carcinoma即将招募NCT06779461研究中心III期2025-01 启动
  12. A Study of AK104+Lenvatinib in Combination With Transarterial Chemoembolization (TACE) Versus TACE in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma正在招募NCT06371157研究中心III期2024-08 启动
  13. Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.正在招募NCT05862337研究中心III期2023-05 启动
  14. A Phase I Clinical Study of Intratumoral Injection Oncolytic Vaccinia Virus GC001 in Patient With Advanced Solid Tumors正在招募NCT06508307研究中心I期2023-04 启动
  15. Chinese HCC Efficacy Evaluation, Response and Safety Study of TareSphere进行中,不再招募NCT06900543研究中心III期2025-04 启动
  16. A Study to Assess the Adverse Events and How Intravenously Infused Livmoniplimab in Combination With Budigalimab Moves Through the Bodies of Adult Chinese Participants With Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC)已终止NCT06487559研究中心I期2024-09 启动
  17. Safety and Efficacy of TareSphere in Patients With Unresectable Hepatocellular Carcinoma已完成NCT06310590研究中心I期2023-08 启动
  18. A Study to Evaluate YH001 in Combination With Toripalimab in Subjects With Advanced NSCLC and HCC已撤回NCT05212922研究中心II期2023-06 启动
  19. A Phase II Study of AK104 Plus Lenvatinib and TACE in HCC进行中,不再招募NCT05319431研究中心II期2022-06 启动
  20. PM8002 in Combination With Chemotherapy as First Line Therapy in Hepatocellular Carcinoma已完成NCT05864105研究中心II期2022-04 启动
  21. A Study of TACE Combined With Atezolizumab Plus Bevacizumab or TACE Alone in Patients With Untreated Heaptocellular Carcionma进行中,不再招募NCT04712643研究中心III期2021-03 启动
  22. Study of HX008 in Combination With Bevacizumab or Lenvatinib for the Treatment of Advanced Hepatocellular Carcinoma (HCC)状态不明NCT04741165研究中心II期2021-01 启动
  23. Safety and Efficacy of Lenvatinib (E7080/MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoembolization (TACE) in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma (MK-7902-012/E7080-G000-318/LEAP-012)已终止NCT04246177研究中心III期2020-05 启动
  24. A Phase III Clinical Trial of AK105 Injection Combined With Anlotinib Hydrochloride Capsules Versus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma (HCC)进行中,不再招募NCT04344158研究中心III期2020-08 启动
  25. To Evaluate the Safety and Efficacy of Microwave Ablation Therapy in Patients With Primary Liver Cancer已终止NCT04520906研究中心不分期2020-12 启动
  26. Evaluate the Safety and Efficacy of Toripalimab Combined With Bevacizumab Versus Sorafenib Therapy for HCC已完成NCT04723004研究中心III期2020-10 启动
  27. A Study of Nofazinlimab (CS1003) in Subjects With Advanced Hepatocellular Carcinoma进行中,不再招募NCT04194775研究中心III期2019-12 启动
  28. A Phase I/II Study of AST-3424 in Subjects With Advanced Solid Tumors进行中,不再招募NCT06239155研究中心I/II期2019-09 启动
  29. Study of BGB-A317 in Participants With Previously Treated Unresectable HCC已完成NCT03419897研究中心II期2018-04 启动
  30. Huaier Granule for Prevention of Recurrence and Metastasis of Hepatocarcinoma Following Local Ablation状态不明NCT03356236研究中心2018-04 启动
  31. A Study of Tislelizumab Versus Sorafenib in Participants With Unresectable Hepatocellular Carcinoma (HCC)已完成NCT03412773研究中心III期2017-12 启动
  32. The Phase III Study of Icaritin Versus Sorafenib in PD-L1 Positive Advanced Hepatocellular Carcinoma Subjects已终止NCT03236649研究中心III期2017-09 启动
  33. A Phase 2 Study of Brivanib in Chinese Patients With Previously Treated Advanced HCC已完成NCT03516071研究中心II期2017-05 启动
  34. STOPPER CHINA:With Tandem Microspheres in the Treatment of Localized Hepatocellular Carcinoma已完成NCT03113955研究中心不分期2017-10 启动
  35. A Phase 1 Study of Fisogatinib (BLU-554) in Patients With Hepatocellular Carcinoma已完成NCT02508467研究中心I期2015-07 启动

打开 PubMed 检索ClinicalTrials.gov

癌症

胃癌

Stomach cancer

2021–2025 年中国大陆作者发表的 9,782 篇胃癌 PubMed 英文论文中,这家医院牵头了 76 篇,占 0.8%。

牵头论文
76
2021–2025 年
牵头试验
17
任何状态,ClinicalTrials.gov
牵头的开放试验
4
正在或即将招募
作为研究中心的开放试验
17
由其他机构牵头
每年牵头的论文数
2021: 5520212022: 121220222023: 202020232024: 191920242025: 20202025

郑州有 4 家医院列在胃癌下全国有 211 家医院列在胃癌下

这家医院参与的开放试验 21

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Fruquintinib Combined With Trastuzumab and XELOX as First-line Treatment in Patients With HER2-positive Advanced Gastric Cancer
    分期
    I/II期
    开始
    2024-02
    登记号
    NCT07334431

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:河南省肿瘤医院郑州

  2. 正在招募
    A Study of Fruquintinib Plus Chemotherapy for Postoperative Treatment of HER2-Negative Gastric Cancer With Poor TRG
    分期
    II期
    开始
    2023-09
    登记号
    NCT06774222

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:河南省肿瘤医院郑州

  3. 正在招募
    Toripalimab Plus FLOT in Locally Advanced Gastric Cancer
    分期
    II期
    开始
    2021-06
    登记号
    NCT04891016

    年龄 18 岁 至 70 岁(登记的条件)

    牵头:河南省肿瘤医院郑州

  4. 即将招募
    Retlirafusp Alfa Combined With Apatinib and Nab-Paclitaxel as Second-line Treatment for Gastric or Gastroesophageal Junction Cancer
    分期
    II期
    开始
    2026-05
    登记号
    NCT07610629

    年龄 18 岁 至 未注明(登记的条件)

    牵头:河南省肿瘤医院郑州

  5. 正在招募
    Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.
    分期
    III期
    开始
    2026-04
    登记号
    NCT07385703

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 64 家列出的医院为研究中心上海、临沂、乌鲁木齐、兰州、北京、南京、南充、南昌、厦门、合肥、天津、太原、安阳、常州、广州、徐州、成都、扬州、承德、昆明、杭州、武汉、汕头、沈阳、洛阳、济南、海口、石家庄、福州、苏州、西安、郑州、重庆、长春、长沙、青岛

  6. 正在招募
    Real-world Effectiveness and Safety of Trastuzumab Deruxtecan in Patients With Locally Advanced or Metastatic HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma in China
    分期
    未注明
    开始
    2025-02
    登记号
    NCT06846996

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 32 家列出的医院为研究中心上海、北京、南京、台州、天津、太原、广州、徐州、杭州、汕头、沈阳、海口、福州、郑州、长春

  7. 正在招募
    A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer
    分期
    III期
    开始
    2025-05
    登记号
    NCT06901531

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 13 家列出的医院为研究中心上海、北京、合肥、哈尔滨、天津、成都、杭州、武汉、石家庄、福州、西宁、郑州

  8. 正在招募
    A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors
    分期
    I期
    开始
    2025-07
    登记号
    NCT07066657

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 9 家列出的医院为研究中心上海、北京、哈尔滨、杭州、武汉、郑州、重庆、长沙

  9. 正在招募
    An Phase Ib/II Clinical Trial of TCC1727 Combination Therapy in Advanced Solid Tumors
    分期
    I/II期
    开始
    2025-12
    登记号
    NCT07371663

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 3 家列出的医院为研究中心北京、杭州、郑州

  10. 正在招募
    Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
    分期
    I/II期
    开始
    2024-06
    登记号
    NCT06324357

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 7 家列出的医院为研究中心上海、南京、哈尔滨、天津、杭州、郑州、长春

  11. 正在招募
    Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)
    分期
    I/II期
    开始
    2024-09
    登记号
    NCT06469944

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 8 家列出的医院为研究中心上海、乌鲁木齐、北京、南昌、厦门、杭州、福州、郑州

  12. 正在招募
    A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer
    分期
    III期
    开始
    2024-11
    登记号
    NCT06532006

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 36 家列出的医院为研究中心上海、乌鲁木齐、兰州、北京、南京、南昌、厦门、合肥、哈尔滨、天津、太原、常州、广州、徐州、成都、杭州、洛阳、石家庄、福州、蚌埠、西宁、郑州、重庆、银川、长春、长沙、青岛

  13. 正在招募
    A Phase 2 Clinical Study of ABSK061 and ABSK043
    分期
    II期
    开始
    2024-11
    登记号
    NCT06632262

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 15 家列出的医院为研究中心上海、厦门、哈尔滨、天津、太原、徐州、成都、杭州、武汉、沈阳、石家庄、襄阳、贵阳、郑州

  14. 正在招募
    Prediction of Peritoneal Metastasis for Gastric Cancer Based on Radiomics
    分期
    未注明
    开始
    2023-01
    登记号
    NCT05722275

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 10 家列出的医院为研究中心北京、太原、广州、昆明、福州、郑州

  15. 正在招募
    Comparing Modified XELOX Plus Sintilimab With Standard XELOX Plus Sintilimab in First-line Treatment for HER2-negative Gastric/Gastroesophageal Junction Adenocarcinoma
    分期
    III期
    开始
    2023-04
    登记号
    NCT05918094

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:中山大学肿瘤防治中心;另有 7 家列出的医院为研究中心上海、南昌、哈尔滨、大连、广州、成都、武汉、郑州

  16. 正在招募
    AI Prediction of Gastric Cancer Response to Neoadjuvant Chemotherapy
    分期
    未注明
    开始
    2023-09
    登记号
    NCT06035250

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 19 家列出的医院为研究中心上海、北京、南宁、天津、广州、昆明、沈阳、福州、苏州、郑州、长沙、青岛

  17. 正在招募
    Perioperative Disitamab Vedotin Plus Toripalimab and XELOX in Gastric or Gastroesophageal Junction Adenocarcinoma.
    分期
    II期
    开始
    2023-11
    登记号
    NCT06155383

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 10 家列出的医院为研究中心北京、厦门、哈尔滨、广州、成都、昆明、济南、福州、郑州

  18. 正在招募
    A Phase I Clinical Study of Intratumoral Injection Oncolytic Vaccinia Virus GC001 in Patient With Advanced Solid Tumors
    分期
    I期
    开始
    2023-04
    登记号
    NCT06508307

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 1 家列出的医院为研究中心郑州

  19. 正在招募
    A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors
    分期
    I/II期
    开始
    2022-01
    登记号
    NCT05150691

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 34 家列出的医院为研究中心上海、北京、南宁、厦门、合肥、天津、安阳、广州、徐州、无锡、杭州、武汉、沈阳、济南、温州、烟台、石家庄、蚌埠、西安、郑州、重庆、长春、长沙

  20. 正在招募
    A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic Cancer
    分期
    I期
    开始
    2022-06
    登记号
    NCT05365581

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 5 家列出的医院为研究中心上海、广州、杭州、武汉、郑州

  21. 正在招募
    Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors
    分期
    I期
    开始
    2021-06
    登记号
    NCT04900818

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 10 家列出的医院为研究中心上海、北京、合肥、哈尔滨、天津、广州、杭州、武汉、沈阳、郑州

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题腹膜转移与晚期化疗与综合治疗影像与人工智能
论文中的科室肿瘤内科普外/肝胆胰外科影像/核医学科放疗科
牵头的论文76
  1. Advanced diffusion-weighted MRI models for preoperative prediction of lymph node metastasis in resectable gastric cancer.2025Abdominal radiology (New York)
  2. A machine learning approach to risk-stratification of gastric cancer based on tumour-infiltrating immune cell profiles.2025Annals of medicine免费全文
  3. Efficacy and safety of XELOX combined with neoadjuvant radiotherapy versus neoadjuvant chemotherapy in locally advanced gastric cancer.2025BMC cancer免费全文
  4. Potential predictive value of CD8A and PGF protein expression in gastric cancer patients treated with neoadjuvant immunotherapy.2025BMC cancer免费全文
  5. Comparison of 2D and 3D measured iodine concentration of gastric adenocarcinoma on spectral-CT and their relationship with perineural invasion.2025BMC medical imaging免费全文
  6. Single-arm, open-label, multicentre phase 1b/2 study to evaluate the safety and efficacy of fruquintinib combined with sintilimab and CAPEOX as a first-line treatment for advanced gastric or gastroesophageal junction adenocarcinoma (FUNCTIO2025BMJ open免费全文
  7. Benmelstobart plus anlotinib and chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: A phase 2 study.2025Cell reports. Medicine免费全文
  8. Dual-energy CT radiomics for predicting neoadjuvant chemotherapy response in locally advanced gastric cancer: A dual-vendor validation study.2025European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  9. Sequential dual-energy CT for longitudinal assessment of pathologic response to neoadjuvant immuno-chemotherapy in locally advanced gastric cancer.2025European radiology
  10. Camrelizumab plus albumin-bound paclitaxel and S-1 as first-line treatment for patients with human epidermal growth factor receptor 2-negative advanced gastric or gastroesophageal junction adenocarcinoma: a phase 2 trial.2025Frontiers in immunology免费全文
  11. Integrative multi-omics analysis of gastric cancer evolution from precancerous lesions to metastasis identifies a deep learning-based prognostic model.2025Frontiers in immunology免费全文
  12. High expression of CXCL13 predicts a favorable response to immunotherapy by upregulating CXCR5+CD8+ T-cell infiltration in gastric cancer.2025Frontiers in immunology免费全文
  13. Efficacy and safety of programmed cell death protein-1 inhibitor for first-line therapy of advanced gastric or gastroesophageal junction cancer: a network meta-analysis.2025Frontiers in immunology免费全文
  14. Neoadjuvant camrelizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastroesophageal junction adenocarcinoma: a single-arm, phase 2 trial.2025Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association免费全文
  15. Gastric Carcinoma Patients with Advanced Pathological Lymph Node Stage Benefit from Postoperative Radiotherapy: A Retrospective Analysis.2025Journal of gastrointestinal cancer
  16. Efficacy and prognostic factors of PD-1 inhibitors combined with apatinib in advanced diffuse gastric cancer.2025Neoplasma
  17. The downregulation of ubiquitin-specific peptidase 2 indicates a poor prognosis and promotes the progression of gastric cancer through focal adhesion and ECM pathway signaling.2025Scientific reports免费全文
  18. Impact of Tregs on tumor regression in locally advanced G/GEJ cancer patients undergoing neoadjuvant chemoimmunotherapy.2025Scientific reports免费全文
  19. A retrospective multicenter study on the efficacy and safety of disitamab vedotin monotherapy versus combination with anti-PD-1 immunotherapy in advanced gastric cancer.2025Scientific reports免费全文
  20. Overexpression of CAD in stomach adenocarcinoma tissues and its clinical significance.2025Seminars in oncology
  21. Preoperative Risk Stratification for Gastric Cancer: The Establishment of Dual-Energy CT-Based Radiomics Using Prospective Datasets at Two Centers.2024Academic radiology
  22. Identification of neutrophil extracellular trap-driven gastric cancer heterogeneity and C5AR1 as a therapeutic target.2024Acta biochimica et biophysica Sinica免费全文
  23. A modified left-sided approach of laparoscopic radical distal gastrectomy for improving outcomes: A video vignette.2024Asian journal of surgery
  24. Enhancing exposure and safety in laparoscopic gastrectomy: The anterior approach for duodenum-first procedure-A video vignette.2024Asian journal of surgery
  25. Integrated analysis of the role of PR/SET domain 14 in gastric cancer.2024BMC cancer免费全文
  26. Development and validation of a deep learning model for predicting postoperative survival of patients with gastric cancer.2024BMC public health免费全文
  27. Comprehensive multi-omics analysis of resectable locally advanced gastric cancer: Assessing response to neoadjuvant camrelizumab and chemotherapy in a single-center, open-label, single-arm phase II trial.2024Clinical and translational medicine免费全文
  28. The value of intravoxel incoherent motion diffusion-weighted imaging in predicting perineural invasion for resectable gastric cancer: a prospective study.2024Clinical radiology
  29. Downregulation of HIGD1B induces mitochondria-mediated apoptosis in gastric cancer cells by inactivating Akt and ERK pathways.2024Drug development research
  30. Discovery of novel coumarin-based derivatives as inhibitors of tubulin polymerization targeting the colchicine binding site with potent anti-gastric cancer activities.2024European journal of medicinal chemistry
  31. Predicting pathologic response to neoadjuvant chemotherapy in locally advanced gastric cancer: The establishment of a spectral CT-based nomogram from prospective datasets.2024European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  32. Spectral CT vs. diffusion-weighted imaging for the quantitative prediction of pathologic response to neoadjuvant chemotherapy in locally advanced gastric cancer.2024European radiology
  33. A novel platelets-related gene signature for predicting prognosis, immune features and drug sensitivity in gastric cancer.2024Frontiers in immunology免费全文
  34. HER2+ advanced gastric cancer: Current state and opportunities (Review).2024International journal of oncology免费全文
  35. The SIX2/PFN2 feedback loop promotes the stemness of gastric cancer cells.2024Journal of translational medicine免费全文
  36. A randomized phase 2 study of HLX22 plus trastuzumab biosimilar HLX02 and XELOX as first-line therapy for HER2-positive advanced gastric cancer.2024Med (New York, N.Y.)RCT
  37. Development and validation of a nomogram for predicting survival in gastric signet ring cell carcinoma patients treated with radiotherapy.2024Scientific reports免费全文
  38. Oxaliplatin-induced upregulation of exosomal miR-424-3p derived from human bone marrow mesenchymal stem cells attenuates progression of gastric cancer cells.2024Scientific reports免费全文
  39. Individual Irinotecan Therapy Under the Guidance of Pre-Treated UGT1A1*6 Genotyping in Gastric Cancer.2024Technology in cancer research & treatment免费全文
  40. Application of intravoxel incoherent motion diffusion-weighted imaging for preoperative knowledge of lymphovascular invasion in gastric cancer: a prospective study.2023Abdominal radiology (New York)
  41. lncRNA ELFN1-AS1 upregulates TRIM29 by suppressing miR-211-3p to promote gastric cancer progression.2023Acta biochimica et biophysica Sinica免费全文
  42. Primary gastric melanoma: A case report.2023Asian journal of surgery
  43. Laparoscopic total gastrectomy with partial duodenectomy and cholecystectomy for locally advanced gastric cancer(with video).2023Asian journal of surgery
  44. A male with synchronous multiple primary malignant tumors including gastric, colon and prostate cancer.2023Asian journal of surgery
  45. Immune checkpoint inhibitors enhanced the antitumor efficacy of disitamab vedotin for patients with HER2-positive or HER2-low advanced or metastatic gastric cancer: a multicenter real-world study.2023BMC cancer免费全文
  46. NREP is a Diagnostic and Prognostic Biomarker, and Promotes Gastric Cancer Cell Proliferation and Angiogenesis.2023Biochemical genetics
  47. Increased lncRNA AFAP1-AS1 expression predicts poor prognosis in gastric cancer: Evidence from published studies and followed up verification.2023Cancer medicine免费全文
  48. Multiparametric MRI-based radiomics nomogram for early prediction of pathological response to neoadjuvant chemotherapy in locally advanced gastric cancer.2023European radiology
  49. Spectral CT-based nomogram for preoperative prediction of perineural invasion in locally advanced gastric cancer: a prospective study.2023European radiology
  50. Genetic risk and gastric cancer: polygenic risk scores in population-based case-control study.2023Expert review of molecular diagnostics
  51. Knockdown of kinesin family member 2C restricts cell proliferation and induces cell cycle arrest in gastric cancer.2023Histology and histopathology
  52. Fusobacterium nucleatum Promotes Megakaryocyte Maturation in Patients with Gastric Cancer via Inducing the Production of Extracellular Vesicles Containing 14-3-3ε.2023Infection and immunity免费全文
  53. Long noncoding RNA ZEB1-AS1 attenuates ferroptosis of gastric cancer cells through modulating miR-429/BGN axis.2023Journal of biochemical and molecular toxicology
  54. A Retrospective Cohort Study Examining the Effects of Anti-PD-1 Antibody in Combination with Apatinib in Patients Previously Treated for Her2-Negative Advanced Gastric/Gastroesophageal Junction Cancer.2023Journal of clinical pharmacology
  55. Increased Expression of POSTN Predicts Poor Prognosis: a Potential Therapeutic Target for Gastric Cancer.2023Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  56. Diagnostic and Prognostic Value of CPZ in Patients with Gastric Cancer by Integrated Analysis.2023Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  57. Comparison of MRI and CT-Based Radiomics and Their Combination for Early Identification of Pathological Response to Neoadjuvant Chemotherapy in Locally Advanced Gastric Cancer.2023Journal of magnetic resonance imaging : JMRIRCT
  58. High DCR and Better Survival in Patients with Advanced or Metastatic Gastric Cancer Receiving Anti-Angiogenic TKI plus Chemotherapy: A Real-World Study.2023Technology in cancer research & treatment免费全文
  59. Is single tract jejunal interposition better than double tract reconstruction after proximal gastrectomy?2023Updates in surgery
  60. Dynamic contrast-enhanced and diffusion-weighted MR imaging in early prediction of pathologic response to neoadjuvant chemotherapy in locally advanced gastric cancer.2022Abdominal radiology (New York)
  61. Machine learning analysis for the noninvasive prediction of lymphovascular invasion in gastric cancer using PET/CT and enhanced CT-based radiomics and clinical variables.2022Abdominal radiology (New York)RCT
  62. A novel method for liver retraction in laparoscopic gastric cancer surgery: A video vignette.2022Asian journal of surgery
  63. "Straight-line modular" operation mode of upper pancreatic lymph-node dissection in laparoscopic radical resection of proximal gastric cancer (with Video).2022Asian journal of surgery
  64. Application of the sandwich technique in porta-hepatis lymph-node dissection: A video vignette.2022Asian journal of surgery
  65. "Lateral approach" for infra-pyloric lymphadenectomy in laparoscopic radical gastrectomy: A video vignette.2022Asian journal of surgery
  66. CD142 plays a key role in the carcinogenesis of gastric adenocarcinoma by inhibiting BCL2-dependent autophagy.2022Biochemistry and cell biology = Biochimie et biologie cellulaire
  67. Characterization of gastric cancer stem-like molecular features, immune and pharmacogenomic landscapes.2022Briefings in bioinformatics
  68. Key Targets and Molecular Mechanisms of Active Volatile Components of Rabdosia rubescens in Gastric Cancer Cells.2022Current computer-aided drug design免费全文
  69. A high interferon gamma signature of CD8+ T cells predicts response to neoadjuvant immunotherapy plus chemotherapy in gastric cancer.2022Frontiers in immunology免费全文
  70. A commentary on "Gastrectomy with omentum preservation versus gastrectomy with omentectomy for locally advanced gastric cancer: A systematic review and meta-analysis" (Int J Surg 2021;96:106176).2022International journal of surgery (London, England)
  71. Prognostic and Predictive Model of the Log Odds of the Negative Lymph Node/T Stage Ratio in Resectable Gastric Adenocarcinoma Patients.2022Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary TractRCT
  72. Identification and epidemiological evaluation of gastric cancer risk factors: based on a field synopsis and meta-analysis in Chinese population.2021Aging免费全文
  73. "Sandwich" infrapyloric lymphadenectomy in laparoscopic radical gastrectomy: A video vignette.2021Asian journal of surgery
  74. Discovering the mechanism and involvement of the methylation of cyclin-dependent kinase inhibitor 2A (CDKN2A) gene and its special locus region in gastric cancer.2021Bioengineered免费全文
  75. Polygenic Risk Scores for Prediction of Gastric Cancer Based on Bioinformatics Screening and Validation of Functional lncRNA SNPs.2021Clinical and translational gastroenterology免费全文
  76. A risk signature with inflammatory and immune cells infiltration predicts survival and efficiency of chemotherapy in gastric cancer.2021International immunopharmacology
中文论文(未计入)6
  1. [Clinical analysis of immunotherapy rechallenge in advanced gastric cancer].2023Zhonghua zhong liu za zhi [Chinese journal of oncology]
  2. [Association of genomic instability of CDH1 gene with clinicopathological characteristics of gastric cancer].2022Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics
  3. [Study on the dynamic changes of peripheral platelet-to-lymphocyte ratio in the prognosis of neoadjuvant chemotherapy patients with gastric cancer].2022Zhonghua yi xue za zhi
  4. [Changing trend of incidence and mortality of stomach cancer during 2010-2016 in Henan Province, China].2022Zhonghua zhong liu za zhi [Chinese journal of oncology]
  5. [Quality assessment of guidelines on upper gastrointestinal cancer screening].2021Zhonghua liu xing bing xue za zhi = Zhonghua liuxingbingxue zazhi
  6. [The value of spleen density in predicting prognosis of patients with gastric cancer after curative gastrectomy].2021Zhonghua yi xue za zhi
它在 ClinicalTrials.gov 上的全部试验(任何状态)71
  1. Retlirafusp Alfa Combined With Apatinib and Nab-Paclitaxel as Second-line Treatment for Gastric or Gastroesophageal Junction Cancer即将招募NCT07610629牵头方II期2026-05 启动
  2. Fruquintinib Combined With Trastuzumab and XELOX as First-line Treatment in Patients With HER2-positive Advanced Gastric Cancer正在招募NCT07334431牵头方I/II期2024-02 启动
  3. A Study of Fruquintinib Plus Chemotherapy for Postoperative Treatment of HER2-Negative Gastric Cancer With Poor TRG正在招募NCT06774222牵头方II期2023-09 启动
  4. Toripalimab Plus FLOT in Locally Advanced Gastric Cancer正在招募NCT04891016牵头方II期2021-06 启动
  5. Disitamab Vedotin Combined With Sintilimab and XELOX Perioperative Treatment for Resectable Gastric Caner With HER2 Overexpression状态不明NCT06227325牵头方II期2024-02 启动
  6. RC48 Plus AK105 and Cisplatin in Advanced Gastric Cancer状态不明NCT05313906牵头方II期2022-05 启动
  7. Conversion Therapy of Fruquintinib in Combination With Sintilimab and SOX in Unresectable Gastric Cancer进行中,不再招募NCT05177068牵头方II期2022-05 启动
  8. Camrelizumab Combined With Apatinib for Advanced Gastric or Esophagogastric Adenocarcinoma状态不明NCT04948125牵头方II期2021-04 启动
  9. TQB2450 Plus Anlotinib Combined With Chemotherapy in the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma状态不明NCT04891900牵头方不分期2021-05 启动
  10. Camrelizumab Combined With Albumin-bound Paclitaxel and S-1 in the Treatment of Advanced Gastric Cancer状态不明NCT04675866牵头方不分期2020-08 启动
  11. SHR-1210 Combined With Trastuzumab , Oxaliplatin and Capecitabine for Neoadjuvant Therapy of Gastric Adenocarcinoma/Gastroesophageal Junction Adenocarcinoma进行中,不再招募NCT03950271牵头方II期2020-01 启动
  12. Camrelizumab Combined With FOLFOX Neoadjuvant Therapy for Resectable Gastric and Gastroesophageal Junctional Adenocarcinoma状态不明NCT03939962牵头方II期2019-07 启动
  13. Study of CT and MR in the Gastric Cancer状态不明NCT04028375牵头方2019-09 启动
  14. A Real World Study of Apatinib in Treatment of Patients With Gastric Carcinoma状态不明NCT03735511牵头方2018-11 启动
  15. The Real World Study of Apatinib for Gastric Cancer Treatment in Henan Province状态不明NCT03478943牵头方2016-01 启动
  16. A Clinical Trial of Two Adjuvant Chemotherapy Regimens for Postoperative Gastric Cancer状态不明NCT04351867牵头方(推断)III期2020-09 启动
  17. Irinotecan Plus Thalidomide in Second Line Advanced Gastric Cancer状态不明NCT02401971牵头方(推断)IV期2014-08 启动
  18. Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.正在招募NCT07385703研究中心III期2026-04 启动
  19. A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer正在招募NCT06901531研究中心III期2025-05 启动
  20. A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors正在招募NCT07066657研究中心I期2025-07 启动
  21. An Phase Ib/II Clinical Trial of TCC1727 Combination Therapy in Advanced Solid Tumors正在招募NCT07371663研究中心I/II期2025-12 启动
  22. Real-world Effectiveness and Safety of Trastuzumab Deruxtecan in Patients With Locally Advanced or Metastatic HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma in China正在招募NCT06846996研究中心2025-02 启动
  23. A Phase 2 Clinical Study of ABSK061 and ABSK043正在招募NCT06632262研究中心II期2024-11 启动
  24. A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer正在招募NCT06532006研究中心III期2024-11 启动
  25. Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread正在招募NCT06324357研究中心I/II期2024-06 启动
  26. Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)正在招募NCT06469944研究中心I/II期2024-09 启动
  27. Perioperative Disitamab Vedotin Plus Toripalimab and XELOX in Gastric or Gastroesophageal Junction Adenocarcinoma.正在招募NCT06155383研究中心II期2023-11 启动
  28. A Phase I Clinical Study of Intratumoral Injection Oncolytic Vaccinia Virus GC001 in Patient With Advanced Solid Tumors正在招募NCT06508307研究中心I期2023-04 启动
  29. Comparing Modified XELOX Plus Sintilimab With Standard XELOX Plus Sintilimab in First-line Treatment for HER2-negative Gastric/Gastroesophageal Junction Adenocarcinoma正在招募NCT05918094研究中心III期2023-04 启动
  30. AI Prediction of Gastric Cancer Response to Neoadjuvant Chemotherapy正在招募NCT06035250研究中心2023-09 启动
  31. Prediction of Peritoneal Metastasis for Gastric Cancer Based on Radiomics正在招募NCT05722275研究中心2023-01 启动
  32. A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors正在招募NCT05150691研究中心I/II期2022-01 启动
  33. A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic Cancer正在招募NCT05365581研究中心I期2022-06 启动
  34. Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors正在招募NCT04900818研究中心I期2021-06 启动
  35. A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015)进行中,不再招募NCT06356311研究中心III期2024-05 启动
  36. A Study to Evaluate the Safety and the Activity of S095029 as Part of Combination Therapy in Advanced Gastroesophageal Junction/Gastric Cancers.进行中,不再招募NCT06116136研究中心I/II期2024-08 启动
  37. EP0057 in Combination With Olaparib in Relapsed Advanced Gastric Cancer and Small Cell Lung Cancer已撤回NCT05411679研究中心II期2023-04 启动
  38. Real-World Observational Study to Describe Treatment Patterns in Patients With HER2-Positive Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer in East Asia已完成NCT05606094研究中心2023-03 启动
  39. Safety and Efficacy of CEA-targeted CAR-T for CEA-positive Advanced Malignant Solid Tumors已完成NCT05538195研究中心I/II期2022-06 启动
  40. Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression已完成NCT05052801研究中心III期2022-03 启动
  41. To Evaluate Efficacy and Safety of TT-00420 (Tinengotinib) as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors已完成NCT05253053研究中心I/II期2022-04 启动
  42. Clinical Study of SHR-1701 Plus Chemotherapy as Perioperative Treatment in Subjects With Gastric Cancer已终止NCT05149807研究中心II/III期2022-01 启动
  43. Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer.已终止NCT05111626研究中心III期2022-03 启动
  44. PD1 Combined With Chemotherapy for Adjuvant Treatment of Gastric Cancer进行中,不再招募NCT05180734研究中心III期2022-02 启动
  45. A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Advanced Gastric Cancer.已终止NCT05188209研究中心II期2021-12 启动
  46. A Study of RC48-ADC in Local Advanced or Metastatic Gastric Cancer With the HER2-Overexpression状态不明NCT04714190研究中心III期2021-03 启动
  47. A Study of Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Advanced Gastric Carcinoma已终止NCT04718402研究中心I期2021-03 启动
  48. A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers进行中,不再招募NCT05152147研究中心III期2021-12 启动
  49. Infigratinib in Subjects With GC or GEJ With FGFR2 Amplification or Other Solid Tumors With Other FGFR Alterations状态不明NCT05019794研究中心II期2020-05 启动
  50. Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)-China Extension已完成NCT04882241研究中心III期2020-07 启动
  51. IN10018 Monotherapy or in Combination With Docetaxel in Gastric or GEJ Adenocarcinoma已完成NCT05327231研究中心I期2020-07 启动
  52. Comparing the Efficacy and Safety of Intra-peritoneal Infusion of Catumaxomab and Treatment of Investigator Choice in Patients With Advanced Gastric Carcinoma With Peritoneal Metastasis状态不明NCT04222114研究中心III期2020-10 启动
  53. Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy, Phase 1 Study of CMG901已完成NCT04805307研究中心I期2020-12 启动
  54. Clinical Trial to Evaluate AB011 Injection in Patients With CLDN18.2-positive Advanced Solid Tumors已完成NCT04400383研究中心I期2020-06 启动
  55. Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01)进行中,不再招募NCT04152499研究中心I/II期2020-02 启动
  56. Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CT041 Autologous CAR T-cell Injection进行中,不再招募NCT04581473研究中心I/II期2020-10 启动
  57. Safety and Efficacy of CEA-Targeted CAR-T Therapy for Relapsed/Refractory CEA+ Cancer已撤回NCT04348643研究中心I/II期2020-02 启动
  58. A Study of Niraparib Combined With MGD013 in Patients With Advanced or Metastatic Solid Tumor Who Failed Prior Treatment已终止NCT04178460研究中心I期2020-02 启动
  59. HX008 Plus Irinotecan Versus Placebo Plus Irinotecan as Second-line Treatment in Advanced Gastric Cancer状态不明NCT04486651研究中心III期2020-09 启动
  60. Perioperative Treatment of Combined SOX With Apatinib and Camrelizumab for Oesophagogastric Cancer进行中,不再招募NCT04208347研究中心II/III期2019-12 启动
  61. Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ Cancer已完成NCT04082364研究中心II/III期2019-09 启动
  62. Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859/KEYNOTE-859)已完成NCT03675737研究中心III期2018-11 启动
  63. A Study of Bemarituzumab (FPA144) Combined With Modified FOLFOX6 (mFOLFOX6) in Gastric/Gastroesophageal Junction Cancer已完成NCT03694522研究中心II期2018-09 启动
  64. Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-811/KEYNOTE-811)已完成NCT03615326研究中心III期2018-10 启动
  65. Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859/KEYNOTE-859)-China Extension已撤回NCT04859582研究中心III期2018-11 启动
  66. Incidence of Pancreatic Fistula After Radical Gastrectomy状态不明NCT03391687研究中心2017-12 启动
  67. The Study to Evaluate Toripalimab (JS001) in Patients With Advanced GC, ESCC, NPC, HNSCC状态不明NCT02915432研究中心I/II期2016-12 启动
  68. Efficacy of HIPEC in the Treatment of Locally Advanced Gastric Cancer After radIcal Gastrectomy With D2状态不明NCT02356276研究中心III期2015-05 启动
  69. A Study of BBI608 Plus Weekly Paclitaxel to Treat Gastric and Gastro-Esophageal Junction Cancer已完成NCT02178956研究中心III期2014-10 启动
  70. A Study of Pertuzumab in Combination With Trastuzumab and Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Gastroesophageal Junction or Gastric Cancer已完成NCT01774786研究中心III期2013-06 启动
  71. A Non-Interventional Study of Treatment Pattern and Clinical Outcomes in Chinese Participants With Gastric Cancer已完成NCT01839500研究中心2013-04 启动

打开 PubMed 检索ClinicalTrials.gov

癌症

视网膜母细胞瘤

Retinoblastoma

2021–2025 年没有牵头视网膜母细胞瘤的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

郑州有 5 家医院列在视网膜母细胞瘤下全国有 176 家医院列在视网膜母细胞瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的视网膜母细胞瘤开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

癌症

骨肉瘤

Osteosarcoma

2021–2025 年中国大陆作者发表的 2,257 篇骨肉瘤 PubMed 英文论文中,这家医院牵头了 19 篇,占 0.8%。

牵头论文
19
2021–2025 年
牵头试验
1
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
1
由其他机构牵头
每年牵头的论文数
2021: 7720212022: 2220222023: 3320232024: 2220242025: 442025

郑州有 8 家医院列在骨肉瘤下全国有 570 家医院列在骨肉瘤下

这家医院参与的开放试验 1

依据 ClinicalTrials.gov 在 2026年11月13日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    ARTEMIS-002: HS-20093 in Patients With Relapsed or Refractory Osteosarcoma and Other Sarcomas
    分期
    II期
    开始
    2023-06
    登记号
    NCT05830123

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 11 家列出的医院为研究中心上海、北京、天津、广州、杭州、郑州、长沙

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
论文中的科室病理/检验科肿瘤内科

这些论文过半是实验室或动物研究。

牵头的论文19
  1. Cancer-associated fibroblast exosomal miR-214-3p regulated by hnRNPA2B1 promotes cisplatin resistance by inhibiting ferroptosis.2026International journal of surgery (London, England)
  2. Dual-Functional Interface Engineering of Mesoporous Bioactive Glass via Polydopamine Chelation for 3D-Printed Scaffolds with Synergistic Photothermal Therapy and Enhanced Osteogenesis.2025ACS applied materials & interfaces
  3. Rab27b-mediated CAFs derived exosomal miR-22-3p suppresses ferroptosis and promotes cisplatin resistance in osteosarcoma.2025Cellular signalling
  4. Rab27a+CAF exosomal miR-9-5p promotes osteosarcoma progression via CREBRF/MAPK signaling pathway.2025Cellular signalling
  5. Exosomal miR-20a-5p derived from cisplatin-resistant osteosarcoma cells promotes chemoresistance via Inhibition of ferroptosis through targeting RUNX3.2025Scientific reports
  6. Circ_UBAP2 exacerbates proliferation and metastasis of OS via targeting miR-665/miR-370-3p/HMGA1 axis.2024Environmental toxicology
  7. Inactivation and replantation of the knee joint: an infeasible surgical method.2024World journal of surgical oncology
  8. The promising roles of exosomal microRNAs in osteosarcoma: A new insight into the clinical therapy.2023Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
  9. LncRNA STK4 antisense RNA 1 (STK4-AS1) promoted osteosarcoma by inhibiting p53 expression.2023Cancer biomarkers : section A of Disease markers
  10. COPS3 inhibition promotes cell proliferation blockage and anoikis via regulating PFKFB3 in osteosarcoma cancer cells.2023European journal of pharmacology
  11. Circular RNA circ_UBAP2 facilitates the progression of osteosarcoma by regulating microRNA miR-637/high-mobility group box (HMGB) 2 axis.2022Bioengineered
  12. Construction and validation of a novel gene signature for predicting the prognosis of osteosarcoma.2022Scientific reports
  13. Secondary pneumothorax as a potential marker of apatinib efficacy in osteosarcoma: a multicenter analysis.2021Anti-cancer drugs
  14. Efficacy and safety of anlotinib in patients with unresectable or metastatic bone sarcoma: A retrospective multiple institution study.2021Cancer medicine
  15. TNK2-AS1 upregulated by YY1 boosts the course of osteosarcoma through targeting miR-4319/WDR1.2021Cancer science
  16. The LINC01410/miR-122-5p/NDRG3 axis is involved in the proliferation and migration of osteosarcoma cells.2021IUBMB life
  17. circUBAP2 regulates osteosarcoma progression via the miR‑204‑3p/HMGA2 axis.2021International journal of oncology
  18. Long noncoding RNA LINC01410 promotes tumorigenesis of osteosarcoma cells via miR-497-5p/HMGA2 axis.2021Journal of biochemical and molecular toxicology
  19. lncRNA‑CASC15 promotes osteosarcoma proliferation and metastasis by regulating epithelial‑mesenchymal transition via the Wnt/β‑catenin signaling pathway.2021Oncology reports
中文论文(未计入)3
  1. [Effectiveness evaluation of three-dimensional printed titanium-alloy prosthesis reconstruction after distal tibia tumor segment resection].2022Zhongguo xiu fu chong jian wai ke za zhi = Zhongguo xiufu chongjian waike zazhi = Chinese journal of reparative and reconstructive surgery
  2. [Role of CT and MRI image fusion and computer assisted simulation technique in guiding type Ⅲ and Ⅳ primary pelvic sarcoma surgeries].2022Zhonghua wai ke za zhi [Chinese journal of surgery]
  3. [Hsa_circ_0006948 regulates the proliferation, migration and invasion in osteosarcoma by regulation of the expression of miR-490-3p target ATG7].2021Zhonghua zhong liu za zhi [Chinese journal of oncology]
早期论文(2016–2020 年)7
  1. Retrospective review of the activity and safety of apatinib and anlotinib in patients with advanced osteosarcoma and soft tissue sarcoma.2020Investigational new drugs
  2. MicroRNA-761 suppresses tumor progression in osteosarcoma via negatively regulating ALDH1B1.2020Life sciences
  3. Experimental Study of Somatic Variants of Osteosarcoma by Whole-Exome Sequencing.2020Medical science monitor : international medical journal of experimental and clinical research
  4. Mid- to long-term effects of two different biological reconstruction techniques for the treatment of humerus osteosarcoma involving caput humeri.2020World journal of surgical oncology
  5. Efficacy and safety of apatinib in treatment of osteosarcoma after failed standard multimodal therapy: An observational study.2019Medicine
  6. Knockdown of lncRNA GHET1 inhibits osteosarcoma cells proliferation, invasion, migration and EMT in vitro and in vivo.2018Cancer biomarkers : section A of Disease markers
  7. Correlations Between Hector Battifora Mesothelial-1 (HBME-1) Expression and Clinical Pathological Characteristics and Prognosis of Osteosarcoma Patients.2017Medical science monitor : international medical journal of experimental and clinical research
它在 ClinicalTrials.gov 上的全部试验(任何状态)2
  1. Apatinib Second Line Treatment for Advanced Osteosarcoma and Soft Tissue Sarcomas ,Openting ,Single Center, One-armed Clinical Study.状态不明NCT03163381牵头方II期2017-04 启动
  2. ARTEMIS-002: HS-20093 in Patients With Relapsed or Refractory Osteosarcoma and Other Sarcomas正在招募NCT05830123研究中心II期2023-06 启动

打开 PubMed 检索ClinicalTrials.gov

癌症

胃肠道间质瘤

Gastrointestinal stromal tumour

2021–2025 年中国大陆作者发表的 523 篇胃肠道间质瘤 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.2%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
2
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 1120232024: 0020242025: 002025

郑州有 5 家医院列在胃肠道间质瘤下全国有 240 家医院列在胃肠道间质瘤下

这家医院参与的开放试验 2

依据 ClinicalTrials.gov 在 2026年11月13日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Efficacy and Safety of NB003 in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)
    分期
    II/III期
    开始
    2026-05
    登记号
    NCT07379047

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 31 家列出的医院为研究中心上海、北京、南京、南宁、南昌、合肥、哈尔滨、太原、广州、成都、昆明、杭州、武汉、济南、石家庄、福州、贵阳、郑州、重庆、长春、长沙、青岛

  2. 正在招募
    A Study of HQP1351 in Patients With GIST or Other Solid Tumors
    分期
    I期
    开始
    2018-07
    登记号
    NCT03594422

    年龄 12 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 5 家列出的医院为研究中心上海、北京、广州、武汉、郑州

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
论文中的科室普外/肝胆胰外科
牵头的论文1
  1. A case of gene mutation responsible for GIST drug resistance.2023Asian journal of surgery
它在 ClinicalTrials.gov 上的全部试验(任何状态)2
  1. Efficacy and Safety of NB003 in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)正在招募NCT07379047研究中心II/III期2026-05 启动
  2. A Study of HQP1351 in Patients With GIST or Other Solid Tumors正在招募NCT03594422研究中心I期2018-07 启动

打开 PubMed 检索ClinicalTrials.gov

癌症

神经母细胞瘤

Neuroblastoma

2021–2025 年中国大陆作者发表的 1,132 篇神经母细胞瘤 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.09%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 1120232024: 0020242025: 002025

郑州有 6 家医院列在神经母细胞瘤下全国有 321 家医院列在神经母细胞瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的神经母细胞瘤开放试验。

这些数字背后的记录
论文中的科室普外/肝胆胰外科
牵头的论文1
  1. Dyngo-4a Induces Neuroblastoma Cell Differentiation Through The AKT and ERK1/2 Pathway.2023CNS & neurological disorders drug targets

打开 PubMed 检索ClinicalTrials.gov

癌症

尤文肉瘤

Ewing sarcoma

2021–2025 年没有牵头尤文肉瘤的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

郑州有 3 家医院列在尤文肉瘤下全国有 134 家医院列在尤文肉瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的尤文肉瘤开放试验。

这些数字背后的记录
中文论文(未计入)1
  1. [Effectiveness evaluation of three-dimensional printed titanium-alloy prosthesis reconstruction after distal tibia tumor segment resection].2022Zhongguo xiu fu chong jian wai ke za zhi = Zhongguo xiufu chongjian waike zazhi = Chinese journal of reparative and reconstructive surgery
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
  1. A Clinical Study of TK216 in Patients With Relapsed or Refractory Ewing's Sarcoma已完成NCT05046314研究中心II期2024-03 启动

打开 PubMed 检索ClinicalTrials.gov

血液疾病

多发性骨髓瘤

Multiple myeloma

2021–2025 年中国大陆作者发表的 1,676 篇多发性骨髓瘤 PubMed 英文论文中,这家医院牵头了 18 篇,占 1.1%。

牵头论文
18
2021–2025 年
牵头试验
2
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
17
由其他机构牵头
每年牵头的论文数
2021: 4420212022: 2220222023: 4420232024: 2220242025: 662025

郑州有 4 家医院列在多发性骨髓瘤下全国有 175 家医院列在多发性骨髓瘤下

这家医院参与的开放试验 17

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    To Evaluate the Safety of SG2918 in Patients With Relapsed/Refractory Multiple Myeloma
    分期
    I/II期
    开始
    2026-04
    登记号
    NCT07454187

    年龄 18 岁 至 80 岁(登记的条件)

    牵头方不是列出的医院;另有 4 家列出的医院为研究中心杭州、苏州、西安、郑州

  2. 正在招募
    A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma
    分期
    I期
    开始
    2026-05
    登记号
    NCT07477587

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 46 家列出的医院为研究中心上海、北京、南京、南昌、厦门、合肥、哈尔滨、天津、太原、宁波、广州、徐州、成都、无锡、杭州、武汉、沈阳、济南、深圳、温州、潍坊、石家庄、福州、苏州、蚌埠、贵阳、郑州、重庆、长沙、青岛

  3. 正在招募
    Isatuximab-VRd in Transplant-Ineligible Newly Diagnosed Multiple Myeloma Patients
    分期
    未注明
    开始
    2026-06
    登记号
    NCT07663253

    年龄 18 岁 至 未注明(登记的条件)

    牵头:复旦大学附属中山医院;另有 9 家列出的医院为研究中心上海、北京、南宁、南通、广州、成都、昆明、武汉、西安、郑州

  4. 正在招募
    A Clinical Study to Evaluate LVIVO-TaVec200 for the Treatment of Relapsed/Refractory Multiple Myeloma
    分期
    早期I期
    开始
    2025-12
    登记号
    NCT07294625

    年龄 18 岁 至 未注明(登记的条件)

    牵头:江苏省人民医院(南医大一附院);另有 4 家列出的医院为研究中心上海、南京、徐州、西安、郑州

  5. 正在招募
    Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma
    分期
    I期
    开始
    2024-05
    登记号
    NCT06375044

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 7 家列出的医院为研究中心北京、南京、天津、广州、杭州、福州、郑州

  6. 正在招募
    A Clinical Study Comparing SG301 Plus Pomalidomide and Dexamethasone to Placebo Plus Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma Patients
    分期
    III期
    开始
    2024-06
    登记号
    NCT06508983

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 9 家列出的医院为研究中心北京、天津、广州、杭州、武汉、苏州、西安、郑州

  7. 正在招募
    A Study of YKST02 in Participants With Relapsed or Refractory Multiple Myeloma
    分期
    I期
    开始
    2024-06
    登记号
    NCT06574568

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 9 家列出的医院为研究中心北京、哈尔滨、太原、广州、杭州、济南、郑州

  8. 正在招募
    Long-term Follow-up Registry Study of Equecabtagene Autoleucel Injection
    分期
    未注明
    开始
    2024-12
    登记号
    NCT07028970

    年龄未注明(登记的条件)

    牵头方不是列出的医院;另有 5 家列出的医院为研究中心北京、天津、武汉、郑州

  9. 正在招募
    A Clinical Trial of LBL-034 in Patients With Relapsed Refractory Multiple Myeloma
    分期
    I/II期
    开始
    2023-10
    登记号
    NCT06049290

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 20 家列出的医院为研究中心上海、北京、厦门、太原、宁波、广州、杭州、武汉、沈阳、海口、深圳、温州、芜湖、苏州、西安、贵阳、郑州、长春、青岛

  10. 正在招募
    Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
    分期
    III期
    开始
    2022-09
    登记号
    NCT05243797

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 11 家列出的医院为研究中心上海、北京、天津、杭州、武汉、沈阳、济南、温州、郑州、长春

  11. 正在招募
    Mecapegfilgrastim With Chemotherapy for Peripheral Blood Stem Cell Mobilization in MM and Lymphoma
    分期
    II期
    开始
    2022-04
    登记号
    NCT05294055

    年龄 18 岁 至 65 岁(登记的条件)

    牵头:中国医学科学院血液病医院(血液学研究所);另有 6 家列出的医院为研究中心北京、合肥、天津、济南、郑州

  12. 正在招募
    A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
    分期
    III期
    开始
    2022-10
    登记号
    NCT05552222

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 29 家列出的医院为研究中心上海、北京、南京、南宁、南昌、厦门、哈尔滨、天津、常州、广州、成都、杭州、武汉、沈阳、济南、深圳、温州、福州、西安、郑州、重庆、长春、长沙

  13. 正在招募
    A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
    分期
    I/II期
    开始
    2021-09
    登记号
    NCT04973605

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 19 家列出的医院为研究中心上海、北京、南京、南昌、厦门、天津、杭州、武汉、沈阳、石家庄、福州、郑州、重庆、长沙、青岛

  14. 正在招募
    A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments
    分期
    III期
    开始
    2021-10
    登记号
    NCT05020236

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 20 家列出的医院为研究中心北京、南京、南昌、天津、广州、徐州、杭州、武汉、济南、深圳、温州、石家庄、福州、郑州、重庆、长春

  15. 即将招募
    A Clinical Study to Evaluate LVIVO-TaVec400 for the Treatment of Relapsed/Refractory Multiple Myeloma(LB2505-0001)
    分期
    早期I期
    开始
    2026-01
    登记号
    NCT07399444

    年龄 18 岁 至 未注明(登记的条件)

    牵头:中国医学科学院血液病医院(血液学研究所);另有 4 家列出的医院为研究中心南昌、天津、徐州、武汉、郑州

  16. 即将招募
    Clinical Study of TQB2934 Injection in Relapsed/Refractory Multiple Myeloma
    分期
    III期
    开始
    2026-06
    登记号
    NCT07569757

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 38 家列出的医院为研究中心上海、兰州、北京、南京、南宁、南昌、合肥、哈尔滨、太原、广州、徐州、成都、承德、昆明、杭州、株洲、沈阳、泸州、济南、湛江、石家庄、蚌埠、西安、贵阳、郑州、重庆、长沙、青岛

  17. 即将招募
    LCAR-M61S and LCAR-M61D in Treatment of Relapsed/Refractory Multiple Myeloma
    分期
    不分期
    开始
    2024-07
    登记号
    NCT06472479

    年龄 18 岁 至 未注明(登记的条件)

    牵头:江苏省人民医院(南医大一附院);另有 2 家列出的医院为研究中心南京、合肥、郑州

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题干细胞移植复发与耐药联合用药
论文中的科室肿瘤内科
牵头的论文18
  1. Tandem autologous hematopoietic stem cell transplantation in multiple myeloma: A historical perspective and current challenges.2025Annals of hematology免费全文
  2. Emerging role of G protein-coupled receptor class C group 5 member D-directed immunotherapy in multiple myeloma: Advances, resistance and combination strategies.2025British journal of haematology免费全文
  3. Therapeutic options for extramedullary involvement in multiple myeloma.2025Clinical and experimental medicine免费全文
  4. Epirubicin Induces Cell Cycle Arrest in Multiple Myeloma Cells by Downregulating CDC20 Expression.2025Frontiers in bioscience (Landmark edition)
  5. Clinical characteristics and risk factors of infection in initially treated patients with multiple myeloma during the induction period.2025Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy
  6. Impact of type 2 and steroid-Induced diabetes mellitus on prognosis in patients with multiple myeloma.2025World journal of surgical oncology免费全文
  7. Identification of potential immune-related mechanisms related to the development of multiple myeloma.2024Chinese medical journal免费全文
  8. Research Progress on Ferroptosis in Multiple Myeloma.2024Current treatment options in oncology免费全文
  9. Hsa_circ_0111738 Inhibits Tumor Progression and Angiogenesis in Multiple Myeloma by Sponging miR-1233-3p to Regulate HIF-1 Signaling Pathway.2023Archives of medical research
  10. Efficacy and safety of bortezomib plus dexamethasone in patients with refractory primary immune thrombocytopenia: A single-center study.2023Asian journal of surgery
  11. Clonal haematopoiesis of indeterminate potential predicts delayed platelet engraftment after autologous stem cell transplantation for multiple myeloma.2023British journal of haematology
  12. Mitochondrial dysfunction and drug targets in multiple myeloma.2023Journal of cancer research and clinical oncology免费全文
  13. Experimental study on thioredoxin redox inhibitor 1-methylpropyl 2-imidazolyl disulfide promoting apoptosis of multiple myeloma cells in vitro and in vivo.2022European review for medical and pharmacological sciences
  14. Reshaping the tumor microenvironment: The versatility of immunomodulatory drugs in B-cell neoplasms.2022Frontiers in immunology免费全文
  15. Glutathione combined with mecobalamin in the treatment of chemotherapy-induced peripheral neuropathy in multiple myeloma: a retrospective clinical study.2021Annals of palliative medicine
  16. Cereblon modulator CC-885 induces CRBN-dependent ubiquitination and degradation of CDK4 in multiple myeloma.2021Biochemical and biophysical research communications
  17. miR-17-3p promotes the proliferation of multiple myeloma cells by downregulating P21 expression through LMLN inhibition.2021International journal of cancer免费全文
  18. Single VHH-directed BCMA CAR-T cells cause remission of relapsed/refractory multiple myeloma.2021Leukemia免费全文
中文论文(未计入)5
  1. [Research Progress of Clonal Hematopoiesis of Indeterminate Potential in Multiple Myeloma --Review].2022Zhongguo shi yan xue ye xue za zhi
  2. [Clinical analysis of 10 cases with extramedullary plasmacytoma of the head and neck].2022Zhonghua er bi yan hou tou jing wai ke za zhi = Chinese journal of otorhinolaryngology head and neck surgery
  3. [Expression of miR-17-5p in the plasma of patients with multiple myeloma and its role in tumorigenesis and development].2022Zhonghua yi xue za zhi
  4. [PX-12 Promoting Apoptosis of Multiple Myeloma Cell Line H929 Induced by Bortezomib].2021Zhongguo shi yan xue ye xue za zhi
  5. [Treatment of two cases of extramedullary infiltration multiple myeloma with BCMA CAR-T cells].2021Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi免费全文
它在 ClinicalTrials.gov 上的全部试验(任何状态)49
  1. BCMA-CAR-T in Relapsed/Refractory Multiple Myeloma状态不明NCT03664661牵头方I期2018-04 启动
  2. Study of BCMA CAR-T in Multiple Myeloma状态不明NCT03322735牵头方I/II期2017-12 启动
  3. Isatuximab-VRd in Transplant-Ineligible Newly Diagnosed Multiple Myeloma Patients正在招募NCT07663253研究中心2026-06 启动
  4. To Evaluate the Safety of SG2918 in Patients With Relapsed/Refractory Multiple Myeloma正在招募NCT07454187研究中心I/II期2026-04 启动
  5. Clinical Study of TQB2934 Injection in Relapsed/Refractory Multiple Myeloma即将招募NCT07569757研究中心III期2026-06 启动
  6. A Clinical Study to Evaluate LVIVO-TaVec400 for the Treatment of Relapsed/Refractory Multiple Myeloma(LB2505-0001)即将招募NCT07399444研究中心早期I期2026-01 启动
  7. A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma正在招募NCT07477587研究中心I期2026-05 启动
  8. A Clinical Study to Evaluate LVIVO-TaVec200 for the Treatment of Relapsed/Refractory Multiple Myeloma正在招募NCT07294625研究中心早期I期2025-12 启动
  9. Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma正在招募NCT06375044研究中心I期2024-05 启动
  10. Long-term Follow-up Registry Study of Equecabtagene Autoleucel Injection正在招募NCT07028970研究中心2024-12 启动
  11. A Clinical Study Comparing SG301 Plus Pomalidomide and Dexamethasone to Placebo Plus Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma Patients正在招募NCT06508983研究中心III期2024-06 启动
  12. A Study of YKST02 in Participants With Relapsed or Refractory Multiple Myeloma正在招募NCT06574568研究中心I期2024-06 启动
  13. LCAR-M61S and LCAR-M61D in Treatment of Relapsed/Refractory Multiple Myeloma即将招募NCT06472479研究中心不分期2024-07 启动
  14. A Clinical Trial of LBL-034 in Patients With Relapsed Refractory Multiple Myeloma正在招募NCT06049290研究中心I/II期2023-10 启动
  15. Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation正在招募NCT05243797研究中心III期2022-09 启动
  16. Mecapegfilgrastim With Chemotherapy for Peripheral Blood Stem Cell Mobilization in MM and Lymphoma正在招募NCT05294055研究中心II期2022-04 启动
  17. A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma正在招募NCT05552222研究中心III期2022-10 启动
  18. A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma正在招募NCT04973605研究中心I/II期2021-09 启动
  19. A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments正在招募NCT05020236研究中心III期2021-10 启动
  20. Aponermin, Pomalidomide, Dexamethasone for Patients With Relapsed/ Refractory Multiple Myeloma进行中,不再招募NCT06924424研究中心不分期2025-03 启动
  21. Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma进行中,不再招募NCT06158841研究中心III期2024-05 启动
  22. A Phase III Study of Eque-cel in Subjects With Len-refractory RRMM (FUMANBA-03)进行中,不再招募NCT06464991研究中心III期2024-03 启动
  23. A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma进行中,不再招募NCT05572515研究中心III期2023-03 启动
  24. Evaluate the Safety, Tolerability, and Efficacy of ICP-490 in Patients With Relapsed and/or Refractory Multiple Myeloma状态不明NCT05719701研究中心I/II期2023-03 启动
  25. A Clinical Trial of TQB2934 for Injection in Multiple Myeloma Subjects状态不明NCT05646758研究中心I期2023-03 启动
  26. Clinical Study of the Safety and Efficacy of BCMA CAR-NK状态不明NCT05652530研究中心早期I期2022-11 启动
  27. Phase I Study of HRS-3738 in Recurrent and Refractory Non-Hodgkin's Lymphoma and Multiple Myeloma进行中,不再招募NCT05363800研究中心I期2022-06 启动
  28. A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to Treatment进行中,不再招募NCT05455320研究中心III期2022-10 启动
  29. A Study of Daratumumab进行中,不再招募NCT05438043研究中心III期2022-12 启动
  30. A Study of the Efficacy and Safety of Pomalidomide Capsules Combined With Low-Dose Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma状态不明NCT05236621研究中心III期2021-01 启动
  31. SG301 Safety Study in Subjects With Relapsed or Refractory Multiple Myeloma and Other Hematological Malignancies进行中,不再招募NCT04684108研究中心I期2021-11 启动
  32. ATG-010(Selinexor) in Combination With Chemotherapy in RRMM状态不明NCT04877275研究中心II期2021-05 启动
  33. A Study of Evaluating the Safety and Efficacy of ATG-010, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)已完成NCT04939142研究中心III期2021-07 启动
  34. A Ph1/2 Study of EMB-06 in Participants With Relapsed or Refractory Myeloma已终止NCT04735575研究中心I/II期2021-05 启动
  35. APG-2575 Monotherapy or in Combination With Lenalidomide/DXMS in Subjects With Relapsed or Refractory Multiple Myeloma状态不明NCT04674514研究中心I/II期2021-04 启动
  36. A Study Evaluating Safety, Tolerability and Clinical Activity of FHND6091 in Patients With Multiple Myeloma状态不明NCT05271682研究中心I期2021-12 启动
  37. A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma进行中,不再招募NCT05083169研究中心III期2021-10 启动
  38. A Study of Ninlaro in Real World Clinical Practice in China已完成NCT04328662研究中心2020-05 启动
  39. A Phase 1/2 Study of a Fully Human BCMA-targeting CAR (CT103A) in Patients With Relapsed/Refractory Multiple Myeloma (FUMANBA-1)状态不明NCT05066646研究中心I/II期2020-04 启动
  40. Clinical Trial to Evaluate CT053 in Patients With Relapsed and/or Refractory Multiple Myeloma (LUMMICAR STUDY 1)状态不明NCT03975907研究中心I/II期2019-06 启动
  41. TJ202 Combined With Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma已完成NCT03860038研究中心II期2019-01 启动
  42. A Study of Evaluating the Safety and Efficacy of ATG-010 in Relapsed Refractory Multiple Myeloma已完成NCT03944057研究中心II期2019-09 启动
  43. TJ202, Lenalidomide and Dexamethasone vs. Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma已完成NCT03952091研究中心III期2019-03 启动
  44. A Study Designed to Evaluate the Safety and Efficacy of Venetoclax Plus Dexamethasone (VenDex) Compared With Pomalidomide Plus Dexamethasone (PomDex) in Participants With t(11;14)-Positive Relapsed or Refractory Multiple Myeloma.进行中,不再招募NCT03539744研究中心III期2018-10 启动
  45. A Study of Modakafusp Alfa on Adult Participants With Relapsed/Refractory Multiple Myeloma已终止NCT03215030研究中心I/II期2017-10 启动
  46. A Study of VELCADE (Bortezomib) Melphalan-Prednisone (VMP) Compared to Daratumumab in Combination With VMP (D-VMP), in Participants With Previously Untreated Multiple Myeloma Who Are Ineligible for High-Dose Therapy (Asia Pacific Region)已完成NCT03217812研究中心III期2017-11 启动
  47. Carfilzomib in Combination With Dexamethasone (Kd) in Chinese Patients With Relapsed & Refractory Multiple Myeloma已完成NCT03029234研究中心III期2017-03 启动
  48. A Study to Compare Daratumumab, Bortezomib, and Dexamethasone (DVd) vs Bortezomib and Dexamethasone (Vd) in Chinese Participants With Relapsed or Refractory Multiple Myeloma已完成NCT03234972研究中心III期2017-11 启动
  49. Phase 3 Study on the Efficacy and Safety of Tanezumab in Patients With Cancer Pain Due to Bone Metastasis Who Are Taking Background Opioid Therapy已完成NCT02609828研究中心III期2015-10 启动

打开 PubMed 检索ClinicalTrials.gov

血液疾病

B 细胞急性淋巴细胞白血病

B-cell acute lymphoblastic leukaemia

2021–2025 年没有牵头B 细胞急性淋巴细胞白血病的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
2
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
2
由其他机构牵头

郑州有 3 家医院列在B 细胞急性淋巴细胞白血病下全国有 88 家医院列在B 细胞急性淋巴细胞白血病下

这家医院参与的开放试验 2

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Inaticabtagene Autoleucel Injection Treatment for Adult Relapsed or Refractory Acute Lymphocytic Leukemia
    分期
    未注明
    开始
    2024-06
    登记号
    NCT06450067

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 10 家列出的医院为研究中心上海、北京、天津、广州、徐州、成都、武汉、济南、郑州

  2. 正在招募
    A Clinical Study of MK-1045 (CN201) in People With Precursor B-cell Acute Lymphoblastic Leukemia (MK-1045-002)
    分期
    I/II期
    开始
    2022-11
    登记号
    NCT05579132

    年龄 2 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 9 家列出的医院为研究中心天津、广州、徐州、成都、杭州、武汉、郑州、重庆

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

血液疾病

再生障碍性贫血

Aplastic anaemia

2021–2025 年中国大陆作者发表的 412 篇再生障碍性贫血 PubMed 英文论文中,这家医院牵头了 4 篇,占 1.0%。

牵头论文
4
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 1120222023: 1120232024: 1120242025: 002025

郑州有 2 家医院列在再生障碍性贫血下全国有 63 家医院列在再生障碍性贫血下

截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的再生障碍性贫血开放试验。

这些数字背后的记录
研究主题干细胞移植儿童

打开 PubMed 检索ClinicalTrials.gov

血液疾病

血友病 A

Haemophilia A

2021–2025 年中国大陆作者发表的 272 篇血友病 A PubMed 英文论文中,这家医院牵头了 1 篇,占 0.4%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
1
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

郑州有 5 家医院列在血友病 A下全国有 132 家医院列在血友病 A下

这家医院参与的开放试验 1

依据 ClinicalTrials.gov 在 2026年11月13日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    To Evaluate the Clinical Study of GS1191-0445 Injection in the Treatment of Hemophilia A
    分期
    III期
    开始
    2025-03
    登记号
    NCT06833983

    年龄 18 岁 至 65 岁;仅男性(登记的条件)

    牵头方不是列出的医院;另有 13 家列出的医院为研究中心兰州、北京、南京、南昌、合肥、唐山、天津、广州、昆明、武汉、济南、郑州、长沙

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
牵头的论文1
  1. Sequential combined bypassing therapy in haemophilia patients with high titer inhibitors: surgical experience.2025Annals of hematology
早期论文(2016–2020 年)2
  1. [Perioperative application of recombinant human coagulation factor Ⅶa combined with prothrombin complex in two hemophilia A patients with high titer inhibitor].2020Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
  2. [Post-transplantation lymphoproliferative disorder accompanies acquired hemophilia after haploid hematopoietic stem cell transplantation in a pediatric AML patient: a case report and literature review].2019Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
它在 ClinicalTrials.gov 上的全部试验(任何状态)13
  1. To Evaluate the Clinical Study of GS1191-0445 Injection in the Treatment of Hemophilia A正在招募NCT06833983研究中心III期2025-03 启动
  2. Study of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein (FRSW107) as Prophylactic Treatment.进行中,不再招募NCT07684898研究中心III期2026-06 启动
  3. Study of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein (FRSW107) On-Demand Treatment进行中,不再招募NCT07663903研究中心III期2026-04 启动
  4. A Clinical Study of Recombinant Human Coagulation Factor VIII for Injection in Patients With Severe Hemophilia A进行中,不再招募NCT06297655研究中心III期2024-11 启动
  5. Safety and Efficacy of STSP-0601 in Adult Patients with Hemophilia a or B with Inhibitor已完成NCT06289166研究中心II期2024-03 启动
  6. SS109 and NovoSeven ® PK / PD Profile, and Preliminary Efficacy and Safety of SS109 on Demand Treatment已完成NCT06010953研究中心I/II期2023-10 启动
  7. Phase 3 Clinical Project of Pegylated Recombinant Human Coagulation Factor VIII-Fc Fusion Protein已完成NCT06142552研究中心III期2023-12 启动
  8. Safety and Efficacy of STSP-0601 in Adult Patients With Hemophilia A or B Without Inhibitor已完成NCT05619926研究中心II期2023-01 启动
  9. A Phase I of SS109 in Hemophilia A or and B With Inhibitors已完成NCT05651061研究中心I期2022-12 启动
  10. Phase III Expansion Trial for Determining the Safety and Efficacy of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection in Adolescent and Adult Patients With Hemophilia A已完成NCT04845399研究中心III期2021-04 启动
  11. An Open Label Study to Determine the Safety and Efficacy of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection in Adolescent and Adult Patients With Hemophilia A.已完成NCT04456387研究中心III期2020-10 启动
  12. Safety, Efficacy Evaluation of Recombinant Coagulation Factor VIII Injection in Subjects With Hemophilia A.状态不明NCT04061109研究中心III期2019-05 启动
  13. Pharmacokinetics Evaluation of Recombinant Coagulation Factor VIII Injection in Subjects With Hemophilia A.状态不明NCT04060836研究中心I期2019-05 启动

打开 PubMed 检索ClinicalTrials.gov

其他疾病

家族性腺瘤性息肉病

Familial adenomatous polyposis

2021–2025 年中国大陆作者发表的 59 篇家族性腺瘤性息肉病 PubMed 英文论文中,这家医院牵头了 1 篇,占 1.7%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

郑州有 1 家医院列在家族性腺瘤性息肉病下全国有 74 家医院列在家族性腺瘤性息肉病下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的家族性腺瘤性息肉病开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

联系这家医院

出示给工作人员或司机的院名卡

河南省肿瘤医院

Henan Cancer Hospital

郑州

大医院往往有多个院区,出发前请先向医院确认院区。

中英对照的咨询信

填写方括号中的内容后,通过医院国际医疗部或官网上的联系方式发送。在这里输入的内容不会离开您的设备。

医院通常需要的资料

  • 主治医生近期的病情总结或信件
  • 病理报告
  • 影像检查(CT、MRI、PET)及报告,尽量附影像文件
  • 已接受的治疗及时间
  • 目前用药

下一步建议

与主治医生沟通可将本页分享给主治医生,一同评估该团队的研究方向是否相关。
确认团队现状论文发表通常滞后数月,医生也可能调动。请在医院官网查询相关科室。
直接联系医院请通过医院官方公布的渠道联系。医院不向我们支付任何费用;是否接诊由医院决定。

这些数字从哪里来

论文

2021–2025 年 PubMed 英文论文中,第一作者或最后作者的第一单位是这家医院的论文。 定义

试验

ClinicalTrials.gov 上列出这家医院为牵头方或研究中心的记录,截至 2026年11月8日。

编号与其他名称

ROR Wikidata
Affiliated Cancer Hospital of Zhengzhou University; Henan Cancer Hospital Affiliated to Zhengzhou University; Henan Cancer Hospital/Institute; Henan Cancer Hospital & Institute; Henan Cancer Hospital and Zhengzhou University Cancer Hospital; Cancer Hospital of Zhengzhou University and Henan Cancer Hospital

提出更正下载数据